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1. INTRODUCTION 
1.1 History and Background 
Emil Fischer, Nobel laureate in chemistry in 1902, attributed the name purine to the fused 
imidazo[4,5-d]pyrimidine compound (1) in 1884 and achieved its synthesis in 1898. [1] 
He further showed through a series of elegant transformations that the natural substances 
adenine, xanthine, caffeine, uric acid, and guanine correspond to different hydroxyl and 
amino derivatives of this fundamental system. [2] 
N
N NH
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1  
Purines are of great interest for several reasons, but in particular, together with certain 
pyrimidines bases, they are constituents of DNA and RNA and consequently of 
fundamental importance in life processes. Additionally, as nucleosides and nucleotides 
they act as hormones and neurotransmitters and are present in few co-enzymes. The inter- 
conversion of mono-, di-, and triphosphate esters of nucleosides are at the heart of 
energy-transfer in many metabolic systems and are also involved in intracellular 
signaling. This central biological importance, together with medicinal chemists search for 
Anti-tumor and Anti-viral (particularly Anti-AIDS) agents have resulted in a rapid 
expansion of purine chemistry in recent years. There are significant lessons to be learnt 
from the chemistry of purines since their reactions exemplify the interplay of its 
constituents imidazole and pyrimidines rings just as the properties of indole which both 
ultimately show modified pyrrole and modified benzene chemistry. Thus purines can 
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undergo both electrophilic and nucleophilic attack at carbon in the five-membered ring 
but only nucleophilic reactions at carbon in the six-membered ring. 
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The numbering of purine ring system is anomalous and reads as if purine were as 
pyrimidines derivative. There are in principle four possible tautomer of purine containing 
an N-hydrogen; in the crystalline state, purine exists as the 7H-tautomer, however in 
solution both 7H-and 9H-tautomer (2) are present in approximately equal proportions; the 
1H- and 3H- tautomer are not significant. [3] 
N
N NH
N
NH2
Adenine (3)
HN
N NH
N
O
H2N
Guanine (4)
HN
N NH
N
O
Hypoxanthine (5)  
Not surprisingly, because the naturally occurring purines are amino and/or oxygenated 
substances, the majority of reported purine chemistry pertains to such derivatives. Since 
the study of purines stems from interest in the naturally occurring derivatives, a ‘trivial’ 
nomenclature has evolved which is in general usage. A nucleoside is as sugar (generally 
9-(riboside) or 9-(2’-deoxyriboside)) derivatives of purine base (or pyrimidines base), for 
example adenosine is the 9-(riboside) of adenine, itself the generally used trivial name for 
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6-aminopurines (3). A nucleotides is a 5’-phosphate (or di or tri-phosphate) of a 
nucleoside –adenosine 5’-triphosphate (ATP) is an example. (10) 
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Caffeine (12) (1,3,7-trimethylxanthine) is the well known stimulant present in tea and 
coffee. In mammals, the end product of metabolic breakdown of nucleic acids is urea but 
in birds and reptile it is uric acid; uric acid was one of the first heterocyclic compounds to 
be isolated as a pure substance, for it was obtained from gallstones by Scheele in 1776. 
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Uric acid (13)  
6-Mercaptopurine (14) is used in the treatment of leukemia and other cancers, Acyclovir 
(15) is an anti-viral agent used in the treatment of Herpes infections, and Dideoxyinosine 
(DDI 16) is used in the treatment of AIDS. 
HN
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Isosteres (i.e. molecules of the same shape but with different atoms combinations) of 
purines are also important as medicines: Allopurinol (17) is used to treat gout and 
Sildenafil (18) achieved international fame, under the trade name ViagraTM, for the 
treatment of impotence. Some natural products can be viewed as purine isosteres: 
Oxanosine (19) and Tubercidin (20), both obtained from Streptomyces, have anti-
microbial and anti-cancer activity. [4] 
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Sildenafil (18) Oxanosine (19) Tubercidin (20)
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1.2 Glimpses of Biological Activity Displayed By Purines 
1.2.1 Interferon inducers 
Interferon (IFN) therapy for chronic hepatitis C is presently based on interferon-α alone 
or in combination with ribavirin. This treatment is associated with a loss of efficacy as a 
result of neutralizing antibodies against exogenous IFN. A new strategy under 
consideration for treating virus infections is to induce endogenous IFN synthesis with 
orally bioavailable small molecular-weight compounds such as imiquimod (21). This 
compound ultimately failed in clinical trials, but a new series of 2-substituted 8-
hydroxyadenines has been identified, including the purine derivatives (22) and (23), 
which are 100- and 30-fold, respectively, more potent than imiquimod and display 
excellent bioavailability. [5-7] The mechanism of actions of these compounds are under 
investigation. 
N
N
N
NH2
Imiquimod (21)
N
N N
N
NH2
OH
X
O
Me
(22) X=O:2171 IU/mL of IFN induction
(23) X=NH: 974 IU/mL of IFN induction
        in mice at 1mg/kg
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1.2.2 Microtubule assembly inhibitors and reversal of differentiation 
Schultz and collaborators have shown that myoseverin (24) is a potent microtubule-
disassembling compound. [8] The low toxicity of myoseverin and analogs suggests that 
they might find use as cytostatic antitumor agents. Myoseverin was found to arrest the 
cell cycle at the G2/M transition by interfering with spindle assembly. The N9 cyclohexyl 
derivative (25), myoseverin B is an improved nontoxic inhibitor of microtubule assembly 
and is currently undergoing evaluation as an anticancer drug candidate. [8] In a 
subsequent in vitro screen of a 1561 compound library, 15 purine derivatives were 
identified that destabilized microtubules without targeting tubulin directly, resulting in 
small spindles. The potential target was NQO1, a NADP-dependent oxidoreductase which 
allowed the identification of a novel factor required for microtubule morphogenesis and 
cell division. The most potent compound diminutol (26) was studied in detail. By 
screening a much larger library of 100,000 small molecules, the Schultz group further 
discovered purmorphamine (27) and reversine (28). Purmorphamine, [9,10] a 2,6,9-
trisubstituted purine, induces osteoblast differentiation of multipotent mesenchymal 
progenitor cells and lineage-committed reosteoblasts. Mesenchymal stem cells (MSC) are 
capable of differentiating into a number of cell lineages, such as bone, cartilage, adipose, 
muscle, stroma, and tendon, and play important roles in repair and regeneration. 
Reversine, [11] a 2,6-disubstituted-purine has the remarkable property of inducing 
myogenic lineage-committed cells to become multipotent mesenchymal progenitor cells 
which can proliferate and re-differentiate into bone (osteoblasts) and fat cells 
(adipocytes). 
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1.2.3 Inhibitors of Hsp90 
Hsp90 is a chaperone required for the ATP-dependent refolding of denatured or unfolded 
proteins, and for the conformational maturation of oncogenic signaling proteins, including 
HER-2/ErbB2, Akt, Raf-1, Cdk4, cMet, Flt-3, Polo-1 kinase, Bcr-Abl, mutated p53. . 
.[12,13] Client proteins that are unchaperoned are ubiquitinated and subsequently 
degraded by the proteasome. As Hsp90 inhibition induces the proteasomal degradation of 
Hsp90 client proteins, Hsp90 represents a unique target for cancer therapeutics. [14,15] 
Important in this context is the observation that the ansamysins, geldanamycin and 17-
AAG, the first Hsp90 inhibitors identified, were found to exhibit a 100-fold higher 
binding affinity for Hsp90 derived from tumor cells over Hsp90 from normal cells. 
Unlike the two ansamysins, which are only moderately active and insoluble, the purine 
derivatives PU3 (29) and Pu24FCl (30) are potent drug-like small molecule inhibitors of 
Hsp90. [16,17]  
The synthesis of a series of 8-arylsulfanyl analogs of PU3 was more recently undertaken 
to study the influence of the aryl moiety on activity. The 8-arylsulfanyl adenine 
derivatives (31), (32), and (33) retained the activity of the methylene-linked compounds 
(29) and (30). As the synthesis of these sulfanyl compounds was more amenable to 
analog production, extensive SAR studies were thus made. Compound (34) is the most 
potent and selective purine-based Hsp90 inhibitor to date [IC50 = 30 nM, SI (tumor vs 
normal cells) = 730- to 3200-fold depending on the cell type]. [13] 
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N
N N
N
NH2
R3
R2
R1
OMe
OMeMeO
(29) PU3: R1=H; R2=H; R3=Et
(30) PU24FCl:R1=Cl; R2=F
        R3=propargyl; (EC50=0.45µM;hsp90)
N
N N
N
NH2
S X
R2
MeO R1
(31) X=Br; R1=R2=H
(32) X=I; R1=R2=H
(33) X=Cl; R1=R2=OMe
N
N N
N
NH2
S Br
OO
(34)  
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1.2.4 Antimycobacterial purines 
Despite the availability of very potent antitubercular agents, tuberculosis remains of great 
concern due to the development of highly drug-resistant forms of the disease. Promising 
new agents have been identified through the screening of libraries of 6-thio-N9-
substituted purines. [18,19] In particular, (6-decylsulfanyl-purin-9-yl)-acetic acid ethyl 
ester (35) and the dodecyl derivative (36) exhibited MIC values of 1.56 and 0.78 µg/mL, 
respectively, against the Mtb H37Rv strain. [20] Compounds (37) and (38) were also 
found highly active against M. tuberculosis (MIC = 1.56 and 0.39 µg/mL, respectively) 
with low toxicity against mammalian cells. Their mechanism of action is not yet known. 
[21] Anti-mycobacterium tuberculosis activity has also been reported for Agelasine F 
(39), a 7,9-dialkylpurinium salt isolated from marine sponges (Agelas sp.). This activity 
was accentuated for analogs (40) and (41) obtained by synthesis. [22] 
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N
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N
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1.2.5 Inhibitors of leukotriene A4 hydrolase 
Leukotriene A4 hydrolase is a key enzyme in the biosynthesis of leukotriene B4 (LTB4). 
This enzyme is a potent pro-inflammatory mediator implicated in the pathogenesis of a 
number of diseases, including inflammatory bowel disease, psoriasis, rheumatoid arthritis 
and asthma. In a recent study at Pharmacia, a series of imidazopyridines and 
imidazopyrimidines (purines) like (42) were tested and shown to exhibit improved 
activities over the known clinical candidates SC-57461A and SC-56938. [23] 
N
N N
N
O
rhLTA4 hydrolase: IC50=47nM
O
R
SC-57461A: R= NMe
COOH
SC-56938: R=
N
COOEt
42  
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1.2.6 Sulfotransferase inhibitors 
Sulfotransferases catalyze the transfer of a sulfonate group from the universal sulfate 
donor PAPS (3’-phosphoadenosine-5’-phosphosulfate) to a hydroxy or amino group of an 
acceptor. This family of enzymes (10 members known to date) plays a role in molecular 
recognition, detoxification, hormone regulation, drug processing, and modulation of 
receptor binding. A primary screen of a purine library by Bertozzi and coworkers [24] 
revealed the 2,6,9-trisubstituted purine (43) to be an inhibitor of carbohydrate 
sulfotransferase NodH from Rhizobium meliloti. Although this molecule also displays 
activity against Cdk2 and p38/MAP kinase, it provided the incentive for the subsequent 
screening of a much larger 35,000 member library of purine and pyrimidine analogs 
against sulfotransferases (ST). This led to the discovery of the potent and selective 
estrogen sulfotransferase (EST) purine inhibitor NG38 (44) (IC50 = 500 nM versus IC50 = 
4000 nM against Cdk1), [25,26] and to (2-chloro-9H-purin-6-yl)-naphthalen-1-ylmethyl-
amine (45), a specific inhibitor of β-arylsulfotransferase-IV (β-AST-IV) (IC50 = 96 nM). 
Sulfotransferases are interesting tools for the study of cancer metastasis and potential 
targets for anti-inflammatory therapy. 
N
N N
N
NH
NH
H2N
O
N
N N
N
NH
Cl
OMe
N
NodH ST: IC50=4000 nM
43
NG38 EST: IC50=500nM
44
N
N NH
N
X
Cl
ß-AST-IV
X=NH: IC50=96nM
X=O   : IC50=70nM
               45  
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1.2.7 Inhibitors of the cysteine protease cathepsin K 
Cathepsin K (Cat K) is a cysteine protease that is highly expressed by osteoclast and bone 
tissue. The primary role of this enzyme is to effect type I collagen degradation, one of the 
main constituents of bone matrix. In a high-throughput screen of a purine library, 
researchers from Novartis identified several interesting hits, including compound (46), a 
novel low nanomolar inhibitor of cathepsin K. The potency and specificity of this 2,6,9-
trisubstituted purine appears to be dependent on the nature of the substituents at the ortho 
position of the 6-anilino motif. Interest in these inhibitors results from the crucial role 
cathepsin K plays in bone matrix resorption. [27] Cat K represents a promising 
therapeutic target for the treatment of osteoporosis. [28] 
N
N N
N
NH
O N
N
NC
Cat K: IC50=7 nM
46  
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1.2.8 Phosphodiesterase inhibitors 
Phosphodiesterases (PDEs) hydrolyze the second messenger molecules cAMP and cGMP 
that are they formed by adenylate and guanylate cyclases, respectively. These second 
messengers are involved in a variety of cellular responses to extracellular agents such as 
hormones and neurotransmitters. There are at least, 11 families of PDEs, some of which 
(PDE4,7 and 8) are specific for cAMP and others (PDE5,6 and 9) for cGMP.  
Additional family members (PDE1-3, 10, and 11) have dual specificity. In addition, PDE 
subtypes occur within the different families, as, for example, the five subtypes PDE4A, 
PDE4B, PDE4D2, PDE4D3, and PDE4D5 for PDE4. A number of potent PDE4 
inhibitors have been developed such as the 2-iodopurine (49). [29] Recently the 3,8-
disubstituted adenine compounds (47) and (48) were shown to be highly potent and 
selective inhibitors of PDE4B, PDE4D3, and PDE4D5. [30] PDE4 inhibitors [29] have 
demonstrated efficacy in models of dermatitis, rheumatoid arthritis, multiple sclerosis, 
autoimmune diseases, and various gastrointestinal and neurologic diseases.  
The 1,2,3,7,8-pentasubstituted purines (50), (51), and (52) are specific nanomolar 
inhibitors of PDE5. [31,32] Some of these PDE5 inhibitors are equipotent to, and more 
selective than, the approved drugs Sildenafil (47a), Vardenafil (47b), and Tadalafil (47c), 
such as (50) which showed good oral bioavailability in both rat and dog with oral efficacy 
in the anesthetized dog erectile function model. [33] Other 8-aryl xanthine derivatives 
such as (53) and (54) function as potent PDE5 inhibitors. [34]  
Aberrant regulation of cAMP levels is involved in asthma, inflammation, immuno-related 
disorders, allergy, and cancer. PDEs are thus connected to a wide range of physiological 
functions and continue to be a major target for drug development. Inhibitors of PDE7 
have been suggested to have broad application for the treatment of lymphoid 
malignancies, [35] Tcell-dependent diseases such as asthma, rheumatoid arthritis, [36] 
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and as immunosuppressants. 6-para-sulfonamidylbenzylamino-substituted 9-ethylpurine 
(55) is a potent and specific inhibitor of PDE7 (PDE1/ PDE7 = 200; PDE3/PDE7 > 5000) 
[37] but poorly soluble in water. Other PDE7 inhibitors are therefore needed for 
application as immunosuppressants and antiasthmatics.  
Compound (56) is one of the most potent inhibitor of PDE1 [32] known to date. 
Inhibition of cGMP hydrolysis by PDE1 and/or PDE5 has been shown to reduce blood 
pressure in hypertensive animals. [32] 
HN
N
N
Me
N
n-Pr
O
OEt
S
N
MeN
O
O
Sildenafil (47a)
N
H
N
N
H
O
O
H
O Me
O
Tadalafil (47c)
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N
N
N
n-Pr
O
OEt
S
N
MeN
O
O
Me
Vardenafil (47b)
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N
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N N
N
I
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O
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OMe
R=
PDE4B, PDE4D3 and PDE4D5
       IC50=9.5, 9, 6.6 nM
                        47
S
R=
PDE4B, PDE4D3 and PDE4D5
          IC50=5.2, 3, 5.5 nM
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1.2.9 Corticotropin-releasing hormone receptor (CRH-R1) modulators 
Corticotropin-releasing hormone is a major modulator of the body’s response to stress. 
Preclinical studies on CRF (corticotropin-releasing factor) agonists and antagonists 
suggested that abnormal CRF secretion or synthesis may underlie the pathologies of 
neuropsychiatric disorders (anxiety, depression, Parkinson’s disease, Alzheimer’s disease, 
alcohol withdrawal etc.) Considerable progress toward the identification of nonpeptide 
modulators of CRF function has been made over the last 10 years. [38] Optimization of 
the pharmacokinetic profiles of a series of pyrrolo-pyridines led to the discovery of 2,6,9-
trisubstituted purine (57) and other 2,6,7,9-tetrasubstituted purinones (58,59). [39] These 
small molecule CRF1 antagonists may be potential anxiolytic and antidepressant agents. 
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1.2.10 Inhibition of nucleoside transport 
Nucleoside transport proteins (NTPs) control the transport of hydrophilic nucleosides 
such as adenosine across the cell membrane. NTPs are subdivided into two families, the 
concentrative nucleoside transporters (CNT), which drive the nucleoside flow against the 
concentration gradient, and the equilibrative nucleoside transporters (ENT), which drive 
the nucleoside flow following their concentration gradient. The ENT is themselves 
divided into four subtypes labeled ENT1 to 4. ENT1 and ENT2 are either sensitive or 
insensitive to inhibition by NBTI (60). [40] The therapeutic application of NBTI (60) has 
been limited due to its poor pharmacological profile, its toxicity, and its lack of in vivo 
efficacy. Compounds (61-63) are inhibitors of ENT-1 with improved pharmacological 
properties. The presence of a bulky susbtituent at the C-8 position of the purine ring (63) 
increased the inhibitory effect significantly. [40,41] 
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1.2.11 Kinase Inhibitors 
[A] Src tyrosine kinase inhibition 
Src is a nonreceptor protein tyrosine kinase which is activated by specific cellular 
receptors and functions as an early transduction signal. Many different compound family 
types have been identified which competitively inhibit Src kinase activity through binding 
in the ATP site. The purine type Src inhibitor NVP-AAK980 (64) has been reported to 
influence bone remodeling. [42] Ariad pharmaceuticals has also been active in this 
domain, demonstrating that bisphosphonate compounds (65) and (66) target bone and are 
potent Src inhibitors (IC50 = 41 and 10 nM, respectively). [42,43] These compounds may 
find application against osteosarcoma and various bone-related disorders (osteoporosis). 
The phosphine oxide AP-23464 (67) [44] is also an exciting new purine compound, in 
that it is a selective and highly potent (IC50 < 1 nM) inhibitor of both Src and Abl kinases, 
with specificity for these enzymes versus more than 40 others tested. [45,46] It thus has 
therapeutic potential for the treatment of Gleevec-resistant chronic myelogenous 
leukemia (CML). [44] Furthermore, AP23464 (67) was very recently shown to strongly 
inhibit the kinase activity of the D816V activation-loop mutant of c-kit, both in vitro 
(IC50=53 nM) and in vivo, and to induce cell-cycle arrest and apoptosis in cells 
expressing this mutation. This molecule is considered to be a promising candidate for 
clinical development for the treatment of systemic mastocytosis (SM) and acute 
myelogenous leukemia (AML). [47] 
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[B] P38α MAP kinase inhibitors 
More than a dozen MAP kinases have been cloned. The best characterized of these are 
extracellular-signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs), and 
p38 (or CSBP2). Significant interest in the MAP kinases as drug targets arose from the 
discovery that specific inhibitors of p38 block the production of proinflammatory 
cytokines (TNF-α, Il-1). [48] This has important implications for the treatment of asthma 
and other inflammatory disorders such as rheumatoid arthritis and Crohn’s disease. [49] 
Using database screening and structure-based design strategies GlaxoSmithKline 
scientists identified the novel p38α inhibitors (68) and (69) (IC50 = 82 and 16 nM, 
respectively) in which the C-6 anilino nitrogen is present as a urea. 
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[C] Inhibitors of Inositol-1,4,5-trisphosphate-3-kinase 
To further demonstrate the usefulness of a purine library that was initially constructed to 
target cyclin-dependent kinases, Schultz and co-workers identified the 2,6-disubstituted 
purine (70) as one of several interesting new leads against IP3K (IC50 = 10–200 lM). [50] 
IP3K phosphorylates inositol 1,4,5-trisphosphate (IP3) to inositol 1,3,4,5-tetra kis phos- 
phate (IP4) and plays an important role in the regulation of intracellular calcium 
concentration. Specific inhibitors of IP3K will be useful tools to study the role of this 
enzyme in transmembrane signal transduction and intracellular calcium metabolism. 
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[D] Cyclin-dependent kinase inhibitors 
Cyclin-dependent kinases (Cdks) are Ser/Thr kinases which, in association with the 
requisite cyclin, play a key role as regulators of the different phases of the cell cycle. To 
date, 13 Cdks and 25 cyclins have been discovered and some of the substrates phosphory- 
lated by the Cdks have been identified. [51,52] The cellular activity of Cdks is, itself, 
regulated by a number of mechanisms including phosphorylations by other kinases, 
dephosphorylations by phosphatases, and the binding of inhibitory peptides that belong to 
the p16INK4A and p21CIP/ p27KIP families. 
The biological response to Cdk inhibitors is complex, but selective in tumor cells. Due to 
their intact G1/S checkpoints, normal cells are shown to be reversibly blocked by Cdk 
inhibitors in either the G1 phase or in the G2/M transition. In transformed cells, where 
these checkpoints are defective or absent, the presence of Cdk inhibitors leads these cells 
to apoptosis. [52,53-55] 
The discovery of Olomoucine (71) [56] and Roscovitine (72) [57] triggered intense 
interest in the development of 2,6,9-trisubstituted purines as selective inhibitors of Cdk1, 
2, and 5. Examples of optimized N-6 anilino/benzylamino inhibitors (73-79), discovered 
for the most part through screening of large libraries of 2,6,9-trisubstituted purines. 
[51,52,57-69] 
Purvalanol A (73) is one of the most potent compounds in this group, but its 
pharmacological profile may be inferior to that for Roscovitine (72). [70] Being more 
orally available, Roscovitine (Seliciclib or CYC202) is currently in phase II clinical trials 
in combination with gemcitabine/cisplatin for non-small cell lung cancer and as a single 
agent for cell malignancies including multiple myeloma. [71]  
Hoechst Marion Roussel [72] synthesized several hundred 2-[trans-(4-amino cyclohexyl 
amino]-6,9-disubstituted purines and screened them against Cdks. For example, 
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compounds (83-87) are highly active inhibitors of Cdk2/cyclin E and generally exhibit 5–
100 times lower activity against Cdk4/cyclin D1. Some of these compounds are 
characterized by the presence of acyclic chains on the 6-position nitrogen, rather than an 
anilino or benzylamino group, as in the aforementioned analogs (71-79).  Albani 
Molecular Research [73] group also synthesized a sizable 2,6,9-trisubstituted purine 
library which contains molecules such as (88-91) which are moderate Cdk inhibitors, but 
very potent antiproliferative agents against a number of human transformed cell lines. 
Although these compounds retain substituents at C-2 and N-9 found in other highly active 
Cdk inhibitors, the incorporation of various bis-aryl or bis-heteroaryl substituents at 
position-6 appears to attenuate their activity. One can therefore ask whether the potent 
cytotoxic effect displayed by these purines against tumor cell lines is linked to their anti-
Cdk activity. Further work on these compounds will most probably shed light on this 
question. 
Recently, a new family of O-alkylguanine-based Cdk inhibitors was discovered which 
lack the seemingly crucial secondary amine substituent at C-6. From the crystal structure 
of the initial lead compound (80) (NU2058) with Cdk2 it was determined that it binds in 
the ATP site in yet another orientation. [67,69] As illustrated in Roscovitine (72) forms 
H-bonds to Leu 83 via the C-6 nitrogen substituent and N-7. 
In the NU series, this important donor–acceptor interaction is conserved by flipping the 
adenine ring such that the amino group at C-2 and the nitrogen N-3 interact with the 
backbone carbonyl and NH of Leu 83. Additional H-bonding interactions of the NU 
compounds with ATP-site residues involved N-9 and the backbone C=O of Glu 81 and N-
7 with the side chain amino group of Lys 33. Optimization of the NU compounds led to 
the 2-anilino analog (81) and ultimately to the para-sulfonamidoaniline analog (82) which 
 
 
Introduction…                                                                                                                  28
is a highly potent Cdk inhibitor. The presence of the para-sulfonamide group in this 
molecule permits two further H-bond interactions involving asp 86. 
Cdks are considered to be prime targets for the development of selective inhibitors to treat 
cancer. They may also find application for the treatment of neurodegenerative disorders 
[74] (Alzheimer’s and Parkinson diseases), stroke, ALS, cardiovascular diseases 
(restenosis), viral infections (HIV, Herpes, cytomegalovirus, and papilloma- virus), and 
various parasites (Plasmodium, Trypanosomes, and Leishmania). [52] CYC202 has 
completed phase I trials and is also being explored for use in glomerulonephritis, an 
inflammatory disease associated with kidney cell proliferation. CYC 202 (Roscovitine, 
72) is presently in phase II trial for lung cancer and hematological malignancies. [75] 
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1.2.12 Adenosine receptor ligands 
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in 
the world. There is growing evidence that they could also be promising therapeutic targets 
in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep 
disorders, immune and inflammatory disorders and cancer. After more than three decades 
of medicinal chemistry research, a considerable number of selective agonists and  
antagonists of adenosine receptors have been discovered, and some have been clinically 
evaluated, although none has yet received regulatory approval. However, recent advances 
in the development of selective and potent ligands, as discussed. Extracellular act as a 
local modulators with a generally cytoprotective function in the body. [76] Its effects on 
tissue protections and repair fall into four categories: increasing the ratio of oxygen 
supply to demand; protecting agents ischaemic damage by cell conditioning; triggering 
anti-inflammatory responses; and the promotion of angiogenesis. [77]  
Types of adenosine receptors (ARs) 
There are four known subtypes of adenosine receptors A1, A2A, A2B and A3 each of which 
has a unique pharmacological profile, tissue distribution and effector coupling. [For fig. 
Nature Review 78] 
All four subtypes are members of the superfamily of G-protein-coupled receptors 
(GPCRs), and are most closely related to the receptors for biogenic amines. Among the 
human ARs, the most similar are the A1 and A3 ARs (49% sequence similarly) and the 
A2A and A2B ARs (59% similarity). 
Extracellular adenosine levels are quite variable, depending on the tissue and the degree 
of stress experienced, and so the basal levels of stimulation of the four subtype by the 
endogenous agonist ary enormously. The sources of adenosine are either release through 
or equilibrative transporter or as a result of cell damage [79], or nucleotidase-mediated 
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hydrolysis of extracellular adenine nucleotides [80], which have their own signaling 
properties that are mediated by purinergic P2 receptors. Ectonucleotidases, of which the 
apyrase CD39 and the 5’-nucleotidase CD73 are prominent examples, are present on the 
extracellular surface of many tissues and are crucially involved in numerous important 
functions. [80] For example in the brain, CD73 is known as a marker of astrocytes (but 
not neurons). These enzymes rapidly and effectively shift signaling by released adenine 
nucleotides and their products to signaling through ARs. Astrocyte derived adenosine, 
acting on A1ARs, has a central role in the integration of synaptic activity by astrocytes 
that leads to widespread coordination of synaptic network. [81] Adenosine itself is rapidly 
metabolized by adenosine kinase [82] and, to a lesser degree, adenosine deaminase to 
AMP and inosine, respectively, both of which are less active than adenosine at the ARs. 
The development of potent and selective synthetic agonists and antagonists of ARs has 
been the subject of medicinal chemistry research for more than three decades. In addition, 
allosteric enhances of agonist action could allow the effects of endogenous adenosine to 
be selectively magnified in an event-responsive and temporally specific manner, which 
might have therapeutic advantages compared with agonists. [83] AR action might also be 
modulated not only by direct-acting ligand, but by inhibition of the metabolism of 
extracellular adenosine [82] or its cellular uptake. [79] 
Although the basic science suggests that selective AR modulators have promise for 
numerous therapeutic applications, including cardiovascular, inflammatory and neuro- 
degenerative disease, in practice this goal has been elusive. One reason for this is the 
ubiquity of ARs and the possibility of side effects. In addition, species differences in the 
affinity of putatively selective ligands complicate preclinical testing in animal models. 
However, there has been recent impetus towards novel clinical targets, in part as a result 
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of the discovery of the A3AR subtype in the early 1990s and of the elucidation of new 
role for adenosine. 
Glimpses of AR agonists and antagonists 
The main approach for discovering AR agonists has been modification of adenosine 
itself, and the structure-activity relationship of adenosine at ARs have been extensively 
probed. [84] Most of the useful analogues are modified in the N6 or 2-position of the 
adenine moiety and in the 3’-, 4’- or 5’-position of the ribose moiety. Highly selective 
agonists of the various receptor subtypes have been designed through both empirical 
approaches and semi-rational approach based on molecular modeling. [85,86] Similarly, 
the main approach for the discovery of AR antagonists has been modification of xanthine 
such as caffeine and theophylline. [87] A modeling approach combining quantitative 
models of receptor and ligand has been demonstrated to accurately predict the potency of 
antagonist. [88] Molecular modeling of ARs using information from the crystal structure 
of the seven transmembrane protein rhodopsin, supported by mutagenesis studies, has 
also aided in understanding ligand recognition and provided insight into conformational 
dynamics. [85,89] The rest of the part includes the development of selective agonists and 
antagonists for each of the receptor subtypes.  
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A1 Adenosine Receptor Agonists (A1ARs) 
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Agonist selectivity of A1ARs is typically accomplished through substitution at the 
adenosine N6-position, giving rise to compounds such as CPA. The 2-chloro analogue 
CCPA displays slighter greater A1AR affinity than the parent compound CPA. The 
affinities of these N-6 substituted derivatives for A3ARs are often intermediate between 
their respective A1AR and A2AAR affinities. Agonists CPA and CCPA are highly 
selective for the rat A1AR subtype, but less selective in human tissue. S(-)-ENBA is an 
even more potent and selective agonist for human and rat A1AR compared with the three 
other subtype. [90] 
The classical, non selective xanthine antagonists of ARs, theophylline (1,3-dimethyl 
xanthine) and caffeine (1, 3, 7-trimethylxanthine), display micro molar affinity at A1, A2A 
and A2BARs. [76] Potent and selective antagonists of A1ARs have been derived by 
modification of the xanthine, including many 8-aryl and 8-cycloalkyl derivatives. [87] 
One such derivative is such DPCPX, which is highly selective for rat A1AR compared 
with the A2AAR (~500-fold) and less selective at the human A2A and A2BARs. Certain 
non-xanthine antagonists, such as the inverse agonist WRC-0571, derived from adenine, 
are A1AR selective, even compared with the A2BAR. [91] 
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A2A Adenosine Receptor Agonists (A2AARs) 
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Substitution with the small alkyl amide groups at the 5’ position of adenosine, as in the 
non-selective agonist NECA, provides increased potency at all the ARs, and this approach 
was also used to generate CG21680, which is a moderately A2AAR-selective agonist in 
rats (140 fold selectivity for the A2A compared with the A1AR) but not humans. [90] The 
selective agonist ATL-146e has much greater affinity for the A2AAR than CG21680. [92] 
Although most N-6 substituted adenosine agonists are A1AR-or A3AR-selective, the 
agonist DPMA (diastereomeric pair) is more than 30-fold selective for the rat A2AAR 
compared with the rat A1AR and A3AR subtypes, but has similar affinity at human A1, 
A2A and A3ARs. [90,93] 
ZM241,385 and SCH 58261 are highly potent and selective A2AAR antagonists [94,95], 
although ZM241,385 has been shown to bind with intermediate affinity at the human 
A2BAR. The phenolic group ZM241,385 can be radio-iodinated to provide an A2A-
selective radio ligand. [96] KW 6002, CSC and other 8-strylxanthines are selective for 
A2AARs compared with the A1, A2B and A3ARs. [97] However, in dilute solution, these 
compounds suffer from sensitivity to photoisomerization.  
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A2B Adenosine Receptor Agonists (A2BARs)-LUF 5835 
The A2BAR is the least studied subtypes of the AR family. [98] Selective antagonists have 
been reported; however, adenosine derivatives as selective A2BAR agonists remain to be 
developed. Nearly all the agonist is the derivatives of adenosine. A notable exception is 
the development, on the basis of recent patents, of a series of pyridine-3,5-dicarbonitrile 
derivatives by IJzerman and colleagues. [99] These compounds act as AR agonists or 
partial agonists, with varying degree of AR selectivity [99] with LUF5835 being the most 
potent activator of the A2BAR (EC50 of 10nM) 
Xanthines that have been developed as selective antagonists of the A2BAR include 
MRS1754 and MRE 2029-F20, both of which have been prepared as radioligands. [100, 
101] Another selective antagonists, [3H] OSIP339391, has also recently been radio label- 
led for the study of A2BARs. [102] 
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A3 Adenosine Receptor Agonists (A3ARs) 
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The prototypical A3AR agonist IB-MECA (CF101) and the more selective agonist Cl-IB-
MECA have been widely used as a pharmacological probe in the elucidation of the 
physiological role of the most recently identified AR subtype, A3. [103] IB-MECA has a 
~50-fold selectivity for rat A3AR over other subtypes in vitro. The related 4-aminobenzyl 
derivative can radio-iodinated, giving rise to [125I]-I-AB-MECA, which is widely used as 
a high-affinity radioligands for A3ARs. [104] 
The 4’-thio modification of adenosine derivatives, explored for its effect on AR 
selectivity, has produced several highly potent and selective A3AR agonists, such as 
LJ568. [105] Conformational studies of the ribose moiety and its equivalents indicate that 
the ring oxygen is not required and that the North (N) ring conformation is preferred in 
binding to the A3AR. One means of locking the conformation of the ribose-like ring is 
through use of the bicyclo[3.1.0]hexane ring system, which assumes an (N)-envelop 
conformation. [89] Highly selective A3AR agonists were recently reported in the series of 
(N)-methanocarba-5’-uronomide derivatives, including MRS3558 which has a Ki value of 
0.29 nM for the human A3AR. [86]  
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The search for A3AR antagonists began with the discouraging observation that xanthine-
such as caffeine and theophylline, the classical antagonists of A1, A2A and A2BARs-
typically has low binding affinities for the A3AR. [106] Initial findings were reported for 
rat A3AR (before the report of the cloning of the human homologue) and many common 
xanthines have binding affinities of around 100µM for this receptor. The cloning of the 
A3AR from other species facilitated further investigation of this receptor. [107] For sheep 
and human A3ARs xanthines have intermediate affinity (typically 100nM for 8-
phenylanthine analogues). There is a marked species dependence of antagonist affinity 
typically greatly exceeding that at the rat receptor for xanthine and other non-purine 
A3AR antagonists. [108] Therefore, the search for A3AR antagonists turned towards more 
novel heterocyclic systems. [103] 
The screening of diverse chemical libraries resulted in the identification of new high-
affinity hits for the human A3AR, including dihydropyridines, flavonoids, pyridines, 
thiazoles and others, which were then optimized, typically by substitution of aromatic 
rings. [88,89,103] The dihydropyridines derivative MRS1334 (not active at L-type 
calcium channels) and the pyridylquinazoline VUF5574 (not selective in rat) are both 
relatively potent A3AR antagonists, with Ki values of 2.7 and 4.0 nM, respectively, at the 
human subtype. The pyridine derivative MRS1523 is a selective A3AR antagonist in both 
rat and human. PSB-11, which is a selective antagonist for human A3ARs, was tritiated 
for characterization of this receptor. [109] Numerous adenine derivatives have been 
studied as selective antagonists for A1 or A2A ARs, and the adenine derivative MRS 3777 
was recently reported to be highly selective for the human A3AR. [110] 
An alternative approach to designing A3AR antagonists is to start with high-affinity 
adenosine derivatives and truncate the molecule in stage to remove the capacity to 
activate the receptor without compromising high-affinity binding. An initial attempt to 
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find adenine derivatives, such as 9-alkyl-N-6-iodobenzyladenines that displays these 
characteristics was unsuccessful. [103] More successful approach either added 
substituents to adenosine derivatives or rigidified the nucleosides, to reduce their intrinsic 
efficacy. [89] With more systematic studies of structure-activity relationships on 
substitution of adenosine at the N-6, ribose and C2 adenine positions, it became apparent 
that the efficacy at A3ARs is more easily diminished by structural modification than it is 
at the other AR subtypes. [89,90] In some cases, N-6 substitution of adenosine 5’-OH 
derivatives with large groups (e.g. substituted benzyl group or large cycloalkyl rings) 
reduced the maximal efficacy, leading to decreased efficacy at the A3AR. For example, 
CCPA and DPMA, which are full agonists at A1 and A2AARs, respectively, are A3AR 
antagonists. This structural insight was used advantageously to obtain the conformation- 
ally constrained nucleoside MRS1292, which proved to be a selective A3AR antagonist in 
both rat and human. [107] 
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A2A Adenosine Receptor Antagonists 
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A2B Adenosine Receptor Antagonists 
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A3 Adenosine Receptor Antagonists 
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1.2.13 Purine as Antimalarials 
Jersey, De J. et al shows that the malarial parasite Plasmodium falciparum depends on the 
purine salvage enzyme hypoxanthine-guanine-xanthine phosphoribosytransferase 
(HGXPRT) to convert purine bases form the host to nucleotides needed for DNA and 
RNA synthesis. An approach to developing antimalarials drugs is to use HGXPRT to 
convert introduced purine based analoges to nucleotides that are toxic to the parasite. This 
strategy requires that these compounds be good substrates for the parasite enzyme but 
poor substrates for the human counterparts, HGPRT bases with a chlorine atom in the 6-
position or a nitrogen in the 8-position exhibited strong discrimination between P. 
falciparum HGXPRT and human HGPRT. The kcat/Km values for the Plasmodium 
enzyme using 6-chloropurine and 8-azaguinine as substrates were 50-80 fold and 336-
fold higher that for the human enzyme respectively. These and other bases were effective 
in inhibiting the growth of the parasite in vitro, giving IC50 values as low as 1µM. [111] 
N
N NH
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H2N
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N
N NH
N
N
H2N
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1.2.14 Purines as Antiviral  
Introduction 
The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human 
immune system, destroying or impairing their function. In the early stages of infection, 
the person has no symptoms. However, as the infection progresses, the immune system 
becomes weaker, and the person becomes more susceptible to so-called opportunistic 
infections. The most advanced stage of HIV infection is acquired immunodeficiency 
syndrome (AIDS). It can take 10-15 years for an HIV-infected person to develop AIDS; 
antiretroviral drugs can slow down the process even further.  
The Global Situation 
Today, an estimated 34–46 million people are living with HIV/AIDS. Already, more than 
25 million people have died from AIDS so far. Four million children have been infected 
since the virus first appeared. Of the 5 million people who became infected with the virus 
in 2003, 700 000 were children, almost entirely as the result of transmission during 
pregnancy and childbirth, or from breastfeeding. Africa seems to be home to two-thirds of 
the world’s people living with HIV/AIDS, but only 11% of the world’s total population. 
Today, about one in 12 African adults is living with HIV/AIDS. One-fifth of the people 
infected with HIV live in Asia. 
Antiretroviral Therapy 
Standard antiretroviral therapy (ART) consists of the use of at least three antiretroviral 
(ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV 
disease. Huge reductions have been seen in rates of death and suffering when use is made 
of a potent ARV regimen. About 39.5 million people are now living with HIV, of whom 
more than 37 million live in low- and middle-income countries. WHO estimates that at 
least 6.5 million of these people are in need of ART. As of June 2006, 1.65 million people 
 
 
Introduction…                                                                                                                  47
had access to ART in low- and middle-income countries. WHO is providing countries 
with ongoing guidance, tools and support in delivering and scaling up ART within a 
public health approach.  
Global Access to HIV Therapy Tripled in Past Two Years, But Significant 
Challenges Remain 
A new report by the World Health Organization (WHO) and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) shows that the number of people on HIV 
antiretroviral treatment (ART) in low- and middle-income countries more than tripled to 
1.3 million in December 2005 from 400 000 in December 2003. Charting the final 
progress of the "3 by 5" strategy to expand access to HIV therapy in the developing 
world, the report also says that the lessons learned in the last two years provide a 
foundation for global efforts now underway to provide universal access to HIV treatment 
by 2010. In July 2005, the G8 nations endorsed a goal of working with WHO and 
UNAIDS to develop an essential package of HIV prevention, treatment and care with the 
aim of moving as close as possible to universal access to treatment by 2010, a target 
subsequently endorsed by the United Nations General Assembly in September 2005. 
[112] 
The current antiviral drug armamentarium comprises almost 40 compounds that have 
been officially approved for clinical use. Most of the approved drugs date from the last 5 
years, and at least half of them are used for the treatment of human immunodeficiency 
virus (HIV) infections. The other antiviral that are currently available are primarily used 
for the treatment of hepatitis B virus (HBV), herpes virus (herpes simplex virus (HSV), 
varicella-zoster virus (VZV), and cytomegalovirus (CMV)), influenza virus, respiratory 
syncytial virus (RSV) and hepatitis C virus (HCV) infections. Among 40 compounds, 
those possess purine as a core structure is enlisted below with their activity spectrum. 
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?   Abacavir [113]   
Activity spectrum: HIV-1 & 2, NRTIs 
(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol 
succinate (ABC), Ziagen® 
N
N N
N
NH
HO
COOH
COOH
H2N
Abacavir  
?   Didanosine [114]    
Activity spectrum: HIV-1 & 2, NRTIs  
2’,3’-dideoxyinosine (ddI), Videx®, Videx® EC 
HN
N N
N
O
HO
Didanosine
O
 
?   Tenofovir disoproxil fumarate [115]    
Activity spectrum: HIV 1 & 2 and various other retroviruses, and HBV- NtRTI 
Fumarate salt of bis(isopropoxycarbonyloxymethyl)ester of (R)-9-(2-Phosphonylmethoxy 
propyl)adenine, or bis(POC)PMPA, Viread® 
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?   Adefovir dipivoxil [116] 
Activity spectrum: HBV, HIV and other retroviruses, and, to a lesser extent, also herpes 
viruses (HSV, CMV, etc.) 
Bis(pivaloyloxymethyl)ester of 9-(2-phosphonylmethoxyethyl)adenine, or bis(POM)- 
PMEA, Hepsera® 
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? Acyclovir [117]  
Activity spectrum: HSV-1 & 2 and VZV 
9-(2-hydroxyethoxymethyl)guanine, acycloguanosine (ACG), acyclovir, aciclovir (ACV), 
Zovirax® 
HN
N N
N
O
H2N
OHO
Acyclovir  
?   Valaciclovir [118]     
Activity spectrum: as for Acyclovir 
L-valine ester of acyclovir (VACV), Zelitrex®, Valtrex®. 
HN
N N
N
O
H2N
OO
Valaciclovir
O
H2N
 
?   Penciclovir [119]   
Activity spectrum: HSV-1, HSV-2 and VZV 
9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine (PCV), Denavir®, Vectavir® 
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?   Famciclovir [120]    
Activity spectrum: HSV-1, HSV-2 and VZV 
Diacetyl ester of 9-(4-hydroxy- 3-hydroxymethyl-but-1-yl)-6-deoxyguanine (FCV), 
Famvir® 
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O
Famciclovir  
?   Ganciclovir [121]   
Activity spectrum: HSV- 1 & 2 and CMV and some other herpesviruses 
9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), (GCV), Cymevene®, Cytovene® 
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? Valganciclovir [122]   
Activity spectrum: as for GCV 
L-valine ester of ganciclovir (VGCV), Valcyte®. 
HN
N N
N
H2N
OO
OH
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O
O
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?   Neplanocin A and 3-deazaneplanocin A [123] 
Activity spectrum: HIV-1 
N
X N
N
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1.3 Conclusion  
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The objective of this short introduction has been to show the recent advances in the 
exploration of purine-based compounds as chemical-biology tools and to illustrate their 
potential as therapeutic agents to treat an impressively wide range of diseases. As purines 
(ATP, GTP, cAMP, cGMP, NAD, NADP, SAM, PAPS. . .) play an important role in life 
processes, it is a natural reflex to look at the effect of modification of substituents on the 
purine ring on biological activity. The chemistry of purines lends itself willingly to such 
manipulation, and as a consequence extensive and diverse libraries of purine derivatives 
have been prepared bearing different types and combinations of functionality at 
essentially all seven reactive centers on the exterior of the bicycle. Accompanying the 
development of methodology for purine library synthesis has been the development of 
new high-throughput screening assays against a myriad of new protein targets. 
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Great strides have thus been made over the past few years to exploit the biological 
properties of purines, and we now have in hand an impressive number of promising 
purine based drug candidates for the treatment of cancer, rheumatoid arthritis, asthma, 
osteoporosis, diabetes, Parkinson’s disease, HIV and depression.   
There is every reason to believe that new and important therapeutic applications of 
purines are just waiting to be discovered. 
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1.4 Synthetic Approaches 
Purines bearing functionality at one or more of the seven peripheral atoms which make up 
its bicyclic structure can be readily synthesized by well-established routes from 
monocyclic precursors. [124] For instance, N-acylation of ‘diaminopyrimidines’ such as 
(2) and (5) followed by ring closure provides access to 2,8-disubstituted adenines (4) and 
theophyllines/xanthines (7), respectively (Scheme 1). 
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Alternatively, construction of the six-membered ring as in (9) can be achieved through 
reaction of 5-aminoimidazole-4-carboxylic acid derivative (8) with isocyanates or the 
corresponding amides with orthoformates. When higher acid ester (R1CO2Me) derivatives 
are employed, the R1 substituent is introduced at C-2 in the purine product (10) (Scheme 
2). 
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Scheme: 2 
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Polyfunctionalized purines (12) substituted at the 2-, 6-, and 8-positions are also obtained 
through the reaction of suitably activated purine intermediates (11) with heteroatom and 
carbon nucleophiles through SNAr-type substitution and transition metal catalyzed 
coupling reactions. [125-136] N-alkylation/acylation, or Vorbruoggen [137-139] and 
other electrophile based reactions, can also be used to introduce functionality onto the 
nitrogen atoms in the purine ring. An example of this methodology is the highly selective 
N-9 alkylation of purines under Mitsunobu conditions. [132-134] (Scheme 3) 
[132,136,140,141] 
Scheme: 3 
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These reactions have been incorporated into a number of strategies for the construction of 
both targeted and diversity driven compound libraries around the purine scaffold. [129-
133, 142] To illustrate this point, two solid-phase synthesis strategies to purine libraries 
which take into account the greater reactivity of the C-6 versus C-2 position in halo-
substituted purines are presented in Scheme 4. In the first, diversity is introduced at the C-
6 center through reaction of different benzylamino resins with intermediate. (14) The 
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second approach is more flexible in that libraries of 2,6,9-trisubstituted purines are 
obtained from a single sulfur-linked purine resin. (15) [131,133] 
Scheme 4 
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1. AIMS AND OBJECTIVES 
Development of Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) 
The nucleotide reverse transcriptase inhibitors (NtRTIs) such as adefovir [9-(2-
phosphonyl-methoxyethyl)adenine (PMEA)] and tenofovir [(R)-9-(2-phosphonyl 
methoxypropyl)adenine (PMPA)] are already equipped with phosphonate group and 
therefore, need two phosphorylation steps to convert active metabolite (PMEApp and 
PMPApp, respectively). The metabolite then served as alternative substrates (with respect 
to the natural substrate dATP) in the reverse transcriptase reaction, where upon their 
incorporation they act obligatorily as chain terminators [De Clercq, E. Anti-Infect. Ther. 
2003, 1, 21-43]. Akin to the NRTIs such as lamivudine, emtrictitabine, and amdixovir, 
the NtRTIs-adefovir and tenofovir are active not only against HIV but also against 
hepatitis B virus (HBV), which is not surprising because HBV uses for its replication a 
reverse transcriptase that is quite similar to that of  HIV. Adefovir and tenofovir have 
been officially approved, in their oral prodrugs forms adefovir 
dipivoxil[bis(pivoloyloxymethyl)-PMEA, Hepsera] and tenofovir disoproxil [bis (iso- 
propyloxycarbonyloxymethyl)-PMPA]fumarate (Viread), for the treatment of HIV and 
HBV respectively.  
Irrespective to these two drugs, as nucleotide reverse transcriptase inhibitors (NtRTIs), 
none of molecule is available in the markets which will durable to HIV-1 and HBV 
infection.  
Current Approach 
In the current work, the efforts have been made for the synthesis of phosphorylated side 
chain at the 9 and 7- position of the purine core structure, which may convert into active 
metabolite in the phosphorylation step.  
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2. ANTITHETIC ANALYSIS 
Following Reterosynthetic approach is adopted in synthesizing Target Molecules (TM). 
The Synthetic Equivalent (SE) for each step is under mentioned. 
N
N N
N
R
H2N O P
O O
O
TM (ATM 300 Series)
N
N N
N
R'
H2N
O P
O
OO
TM (ATM 200 Series)  
Where, R and R’= Various bases like Morpholine, Piperidine, Piperazine, n-Propylamine, 
n-Butylamine etc and /or primary and secondary amines. 
Step 1 
N
N N
N
R
H2N O P
O O
O
TM
N
N N
N
X
H2N O P
O O
O
Where X=Cl or Br
SE
 
Similarly, one can write the identical SE for 7-isomer (ATM 200 series). 
Step 2 
N
N N
N
X
H2N O P
O O
O
N
N N
H
N
Cl
H2N
TsO O
P
O
O
O
SE  
In this step the SE is similar for 7-isomer. 
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Step 3 
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3. REACTION SCHEMES 
SCHEME 1: Synthesis of Synthon 2-(chloromethoxy)ethyl acetate (ATM 101) 
under Solvent free condition 
O
O Cla
O
O
ATM 101
O
 
 
1.1 Reagents and conditions (a)  
 
? Acetylcholoride and Lewis acid at 80oC or Room temperature 
 
Four Lewis acids were employed for the above transformation. 
 
• ZnCl2 
• AlCl3 
• FeCl3 
• BF3.Et2 
 
1.2 Plausible Mechanism 
OO : :: :
O
Me Cl
..
OO :: : C Me
O O
O
O
Cl
O
O
O
ATM 101
Cl
 
1.3 Experimental procedure for the synthesis of ATM 101 
Method A 
To a oven dried flask, aluminium trichloride (5gm, 0.0168mol, 0.01eq) or zinc chloride or 
ferric chloride (0.5mol) and 1, 3-dioxolane (250gm, 3.37mol, 1eq) was charged. The 
reaction mixture was stirred at room temperature for 30min. Acetylchloride (317.89gm, 
4.049mol, 1.2eq) was added dropwise through addition funnel. After the completion of 
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addition, the reaction mixture was heated up to 80o for an hour. Gradually temperature 
was dropped and the reaction mixture was kept at room temperature for overnight under 
nitrogen. Finally the product was distilled over three temperatures and pressures. 
Discarded the distillate of first and second fraction. The structure of the third fraction was 
confirmed by 1H NMR using CDCl3 as solvent. 
Fractions Temperatures mmHg 
1st fraction 60o 21mm 
2nd fraction 90o 21mm 
3rd Fraction 68o 4mm 
 
Method B 
To a oven dried three neck flask, 1,3-dioxolane (250gm, 3.37mol, 1eq), anhydrous diethyl 
ether (700ml) and BF3.Et2 (0.008 mol) were charged. Acetyl chloride (317.89 gm, 
4.049mol, 1.2eq) in diethyl ether (200ml) was charged through addition funnel and 
maintaining the temperature in between 25-30o. The reaction mixture was stirred 
overnight at room-temperature under nitrogen. From the resulting reaction mixture, 
diethyl ether was stripped in vacuo leaves the crude product. Finally it was distilled at 
three different temperature and pressure as mentioned above. The yield of the final 
product with different Lewis acid catalyst was found as follows. Structure of the product 
(ATM 101) was confirmed by 1H NMR by using CDCl3 as a solvent. 
Lewis acid % Yield Lewis acid % Yield 
AlCl3 85 FeCl3 75 
ZnCl2 89 BF3.Et2 82 
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SCHEME 2: Synthesis of Synthon 2-(methoxy diisopropylphosphite) ethyl 
acetate (ATM 102) under Solvent free condition 
Michaelis-Arbuzov Phosphonate Synthesis 
AcO
O Cl
ATM 101
P
O
O
O
AcO
O P
ATM 102
O
O
O
b
 
2.1 Reagents and conditions (b)  
? Triisopropylphosphite/ 110oC 
2.2 Plausible Mechanism 
AcO
O Cl
ATM 101
P
O
O
O
AcO
O P
ATM 102
O
O
O
: :
:
: :
..
.. AcO
O P O
O
O
Cl
SN2
Cl
 
2.3 Experimental procedure for the synthesis of ATM 102 
To a three-neck flask, ATM 101 (200gm, 1.3107mol, 1eq) was charged and it was heated 
at 110oC temperature. Through addition funnel, triisopropylphosphite (272.95gm, 
1.3107mol, 1eq) was added and the reaction mixture was heated vigorously at 110oC. 
Simultaneously to this, 2-chloropropane (95ml) was removed by distillation during the 
course of reaction. The reaction mixture was heated for about 3h. Finally, the reaction 
mixture was distilled. The main fraction was collected at 3mm at 160o temperature (Yield 
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89%). The structure of the product (ATM 102) was confirmed by 1H NMR by using 
CDCl3 as a solvent. 
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SCHEME 3: Synthesis of Synthon Diisopropyl (2-hydroxyethoxy) 
methylphosphonate (ATM 103)  
ATM 102
AcO
O P
ATM 103
O
O
O
c
HO
O P O
O
O
 
3.1 Reagents and conditions (c)  
? Methanol/HCl at 60o 
3.2 Plausible Mechanism 
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O
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O
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3.3 Experimental procedure for the synthesis of ATM 103 
To a oven dried flask, ATM 102 (175gm) was taken in absolute methanol (500ml). To 
this solution, conc. HCl (12ml) was added and the resulting solution was refluxed for an 
appropriate time. After the completion of reaction as indicated by TLC, methanol was 
removed, leaving crude oil. Remaining water from the reaction mixture was removed by 
azeotropic distillation on rotavap with toluene for about 5-6 hrs. Finally leaves the clear 
oil of neutral pH. The yield of the product was found to be 85%. The structure of the 
synthon (ATM 103) was confirmed by 1H NMR by using CDCl3 as a solvent. 
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SCHEME 4: Synthesis of Synthon 2-((isopropoxyphosphono)methoxy) ethyl 4-
methylbenzenesulfonate (ATM 104) 
ATM 103
HO
O P
ATM 104
O
O
O
d
TsO
O P O
O
O
 
4.1 Reagents and conditions (d)  
? p-Toluenesulphonyl chloride 
? Acetonitrile/80oC 
4.2 Plausible Mechanism 
O
O P O
O
O
d
TsO
O P O
O
O
Me
S
ClO
O
H
..
ATM 103 ATM 104
:
 
4.3 Experimental procedure for the synthesis of ATM 104 
To a stirred solution of synthon ATM 103 (150gm, 0.6660mol, 1eq) acetonitrile (500ml), 
p-toluenesulphonyl chloride (152.38gm, 0.7992mol, 1.2eq) in 250 ml of acetonitrile was 
added dropwise. After the completion of addition, the reaction mixture was refluxed for 
an appropriate time. The reaction was monitored by TLC, acetonitrile was stripped off 
under reduced pressure leaving crude product. Finally, it was purified by silica gel 
column chromatography (60-100 mesh) by using ethyl acetate and hexane as the eluents. 
The structure of synthon (ATM 104) was confirmed by 1H NMR using CDCl3 as a 
solvent.  
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SCHEME 5: Synthesis of Synthons Bis(2-propyl) 9-[2-(Phosphonomethoxy) 
ethyl]-2-amino-6-chloropurine (9-isomer-ATM 300) and  Bis(2-propyl) 7-[2-
(Phosphonomethoxy)ethyl]-2-amino-6-chloropurine (7-isomer-ATM 200) 
ATM 200 and ATM 300 can be synthesized by two methods 
? Method A: From Tosylate 
? Method B: Through Mitsunobu Reaction 
Method A (From Tosylate) 
N
N N
H
N
Cl
H2N
ATM 104
eTsO
O P O
O
O
N
N N
N
Cl
H2N
O P
O
OO
ATM 200 (7-isomer)
N
N N
N
H2N
Cl
O P
O O
O
ATM 300 (9-isomer)
2-Amino-6-chloropurine
 
5.1 Reagents and conditions (e) 
? NaH/DMF, 0o to 25oC  
? 2-Amino-6-chloropurine 
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5.2    Plausible Mechanism 
N
N NH
N
Cl
H2N
ATM 104
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O P O
O
O
N
N N
N
Cl
H2N
O P
O
OO
ATM 200 (7-isomer)
N
N N
N
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O O
O
ATM 300 (9-isomer)
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N N
H
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O P O
O
O
..
..
 
5.3 Experimental procedure for the synthesis of ATM 200 and ATM 300 from 
Tosylate (Method A) 
To an oven dried flask, charge dimethyl formamide (300ml), sodium hydride (8.37gm, 
0.3488mol, 1.1eq) and 2-amino-6-chloropurine (53.78gm, 0.3171mol, 1eq). Stir the 
reaction mixture at 10oC. Synthon ATM 104 (125gm, 0.3171mol, 1eq) was taken into 
DMF (150ml) and added dropwise so that the temperature of the reaction mixture does 
not go beyond 10oC. After the completion of addition of synthon ATM 104, the reaction 
mixture was taken out from bath to achieve room temperature. After the completion of 
reaction as indicated by TLC (MDC:MeOH::8.5:1.5), DMF was stripped off at reduced 
pressure. Resulting crude product was directly charged into silica gel column 
chromatography (60-100 mesh) by using dichloromethane and methanol as eluents. Two 
spots were observed on TLC, both were isolated and characterized by 1H NMR, 13C 
NMR, FT-IR and Mass Spectrometric techniques.  
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Method B: Mitsunobu Reaction 
N
N N
H
N
Cl
H2N
ATM 103
fHO
O P O
O
O
N
N N
N
Cl
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O P
O
OO
ATM 200 (7-isomer)
N
N N
N
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O P
O O
O
ATM 300 (9-isomer)  
5.4 Reagents and conditions (f) 
? Triphenylphosphine 
? Diethylazadicarboxylate (DEAD) 
? Anhydrous dimethyl formamide (DMF)  
? Temperature -10 to 40oC 
5.5     Plausible Mechanism 
N N
COOEt
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N N
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Similar Mechanism can be explained which will lead to the synthesis of ATM 200 (7-
isomer) 
Experimental procedure for the synthesis of ATM 200 and ATM 300 by Mitsunobu 
Reaction (Method B) 
To an oven dried flask, charge 2-amino-6-chloropurine (10gm, 0.0589mol, 1eq), ATM 
103 synthon (14.16gm, 0.0589mol, 1eq), triphenylphosphine (23.22gm, 0.0885) and 
finally anhydrous DMF (150ml). The reaction mixture was warmed at 45oC, then cooled 
between -5 to -10oC. Add DEAD (10.2ml, 0.0585mol) in DMF (50 ml) from dropping 
funnel, the temperature of the reaction mixture was kept at -10oC during this addition. 
The -10oC temperature was maintained for additional 4 hrs, and then removing the flask 
to achieve room temperature. The reaction mixture was stirred over night at room 
temperature. Clear yellow solution was obtained. By TLC (MDC:MeOH::8.5:1.5), the 
reaction completion was confirmed. DMF was stripped down in vacuo. Resulting crude 
reaction mixture was directly charged in to silica gel column (Mesh 60-100) and eluted by 
using dichloromethane and methnol as eluents. Two spots were observed, both the spots 
were isolated and characterized by 1H NMR, 13C NMR, FT-IR and Mass Spectrometric 
techniques.  
The percentage yields of both the isomers i.e 7-isomer and 9-isomers under different 
reaction conditions were found as follows. 
Methods Percentage Yields Mp/oC 
7-isomer-  39% A 
(From Tosylate) 9-isomer-  55% 
150-151oC 
(lit. 152oC)1 
7-isomer-  35% B 
(Mitsunobu reaction) 9-isomer-  62% 
92-93oC 
(lit. 93oC)1 
  
1. Erik De Clercq et al 1999, 42, 2064-2086. 
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4. SPECTRAL DISCUSSION 
1H NMR Spectra 
Proton NMR spectra were recorded on Bruker 300 and 400MHz (Avance-II) instruments 
using DMSO-d6, CDCl3 and D2O as the solvents with tetramethylsilane (TMS) as the 
respective internal standard. Chemical shifts were recorded in (δ) and coupling constants 
were recorded in Hertz (J). Number of protons found in NMR is concomitant with the 
theoretical value. The clear-cut multiplet and doublet pattern indicate the presence of 
isopropyl group. Two triplets were observed due to presence of adjacent methylene group 
in the aliphatic side chain. One more remarkable doublet of methylene group is also 
observed due to the presence of adjacent “P” atom to the methylene group. This 
remarkable doublet is observed in all the spectra having coupling constant (J~7-9). The 
H-8 proton of the purine moiety is little downfield in 7-isomer than the 9-isomer. It is not 
easy to distinguish the spectra of 7-isomer and 9-isomer at a glance but previously 
reported mp of both the compounds and spectral data, the identification of 7 and 9-isomer 
becomes easier. 
13 C NMR Spectra 
13C NMR spectra were recorded on Bruker 400MHz instruments using DMSO-d6 and 
CDCl3 as the solvents with tetramethylsilane (TMS) as the respective internal standard. 
Numbers of carbon present in the purine molecules investigate are comparable with the 
experimental and 13C spectral evidences. The quaternary carbon at position-2 of the 
purine moiety, attached between two nitrogen of the pyrimidine ring and –NH2 appears at 
the most downfield in the spectrum (~160 δ).  
DEPT 135 
Four carbon of the isopropyl group shows the chemical shift ~24 δ is found in upward 
with respect to the solvent. The two –CH of the isopropyl group shows the δ value in 
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between 71-72 upward to the baseline. The charactristic splitting of the methylene carbon 
attached to the phosphorous shows 71-72 δ. Two more methylene group of the aliphatic 
side chain shows the chemical shift 65-67 δ. For more spectral data, please refer the 
spectra of the compounds. 
FT-IR Spectra 
IR spectra were recorded on Shimadzu FTIR-8400 using KBr pellet. The percentage 
transmittance is given in cm-1. Primary amine (1o) present in the compound shows strong 
band at 3408.9-3361.7. Actually two bands are observed. =CH stretching is observed in 
between 3126.4-3198.7. The strong band at 2923.9 and 2976.9 indicates the presence of 
aliphatic C-H stretching. N-H stretched in between 1598.9 to 1561.3. The characteristic 
band is observed at 1194.8 and 1189.0 shows the P-O stretching. Ar-Cl is observed at 
787.9. More interpretation of the spectra is given in spectral data itself. 
Mass spectra 
Mass spectra were recorded on Shimadzu GCMS-QP2010 by using EI technique. In 9-
isomer(ATM 300), (M+) peak is observed at 391 m/z. (M+1) and (M+2) peaks are also 
clearly observed at 392 and 393 m/z while in case of 7-isomer, only molecular ion peak is 
observed at 391. The base peak in ATM-300 is observed at 196 m/z while in 7-isomer, it 
appears at 43 m/z. No particular plausible fragmentation pattern was predicted from the 
spectra. 
Elemental Analysis 
Elemental analysis of the compounds was carried out on Elementar Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned.   
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5. SPECTRAL DATA 
2-(Chloromethoxy)ethyl acetate (ATM 101) 
Mole. Formula C5H9ClO3, Mole. Wt. 152.58 
1H NMR (CDCl3): δ 5.484(s, 2H, -CH2), 4.234(t, 2H, -CH2), 3.864(t, 2H, -CH2), 2.058(s, 
3H, -COCH3). 
Anal. Calc.: C 39.36%, H 5.95%; Anal. Observed: C 39.44%, H 5.89%  
2-(Methoxy diisopropylphosphite)ethyl acetate (ATM 102) 
Mole. Formula C11H23O6P, Mole. Wt. 282.27 
1H NMR (CDCl3): δ 4.675-4.613(m, 2H, 2x-CH), 4.103(d, 2H, J=3.79, -POCH2), 
3.667(d, 4H, 2x-CH2), 1.948(s, 3H, -COCH3), 1.235(s, 6H, 2x-CH3), 1.216(s, 6H, 2x-
CH3). 
Anal. Calc.: C 46.81%, H 8.21%; Anal. Observed: C 46.89%, H 8.30%.  
Diisopropyl (2-hydroxyethoxy)methylphosphonate (ATM 103) 
Mole. Formula C9H21O5P, Mole. Wt. 240.23 
1H NMR (CDCl3): δ 5.356(s, 1H, -OH), 4.797-4.730(m, 2H, 2x-CH), 3.823(d, 4H, 2x-
CH2), 3.742-3.710(m, 4H, 2x-CH2), 1.344(s, 12H, 4x-CH3). 
Anal. Calc.: C 45.00%, H 8.81%; Anal. Observed: C 45.10%, H 8.75%.  
2-((Isopropoxyphosphono)methoxy)ethyl-4-methylbenzenesulfonate (ATM 
104) 
Mole. Formula C16H27O7PS, Mole. Wt. 394.42 
1H NMR (CDCl3): δ 7.789(d, 2H, J= 8.25, Ar-H), 7.353(d, 2H, J=8.379, Ar-H), 4.759-
4.672(m, 2H, -CH), 4.176-4.104(m, 2H, -CH2), 3.795(t, 2H, -CH2), 3.719(d, 2H, J=8.22, -
POCH2), 2.448(s, 3H, -CH3), 1.357-1.232(t, 12H, 4x-CH3). 
Anal. Calc.: C 48.72%, H 6.90%; Anal. Observed: C 48.82%, H 6.95%.  
 
 
Synthesis of 7 and 9-isomers… 
 
81
Bis(2-propyl) 9-[2-(phosphonomethoxy)ethyl]-2-amino-6-chloropurine 
(ATM 300, 9-isomer) 
Mole. Formula C14H23ClN5O4P, Mole. Wt. 391.76 
1H NMR (CDCl3): δ 8.088(s, 1H, H-8), 6.883 (brs, 2H, -NH2), 4.503-4.454(m, 2H, 2x-
CH), 4.239(t, 2H, -CH2), 3.872(t, 2H, -CH2), 3.777(d, 2H, J=8.4, POCH2), 1.255-1.124(d, 
12H, 2x-CH3). 
13C NMR (CDCl3): δ 160.21, 154.55, 149.68, 143.87, 123.62, 70.64, 70.58, 70.38, 65.81, 
64.18, 24.19, 24.15, 24.04, 24.00 
IR (KBr Pellet): 3361.7(-NH2 stretching), 2930.6(C-H stretching), 1614.3(C=C 
stretching), 1561.3(C=C stretching), 1374.2(iPr group, strong doublet), 1353.0(C-N 
stretching, Aromatic), 1315.4(POOiPr2), 1228.6(C-N stretching, Aliphatic), 1104.2(C-O 
stretching),  992.3(P-O-C stretching), 787.9(oop, C-H aromatic), 642.3(C-Cl stretching) 
MS (EI, m/z): 391(M+, 10), 393(M+2, 4), 376(6), 356(3), 336(1), 334(5), 306(2), 
290(20), 272(5), 260(1), 238(1), 225(10), 212(13), 196(100), 195(60), 169(56), 160(27), 
146(9), 134(32), 125(19), 107(9), 95(28), 82(14), 65(16), 43(73), 41(25). 
Anal. Calc.: C 42.90%, H 5.92%, N 17.88%; Anal. Observed: C 42.95%, H 5.88%, N 
82%.  
Bis(2-propyl) 7-[2-(Phosphonomethoxy)ethyl]-2-amino-6-chloropurine  
(ATM 200, 7-isomer) 
Mole. Formula C14H23ClN5O4P, Mole. Wt. 391.76, mp 150-151oC. (lit. 152oC) 
1H NMR (CDCl3): δ 8.0988(s, 1H, H-8), 5.589(brs, 2H, -NH2), 4.724-4.644(m, 2H, 2x-
CH), 4.563(t, 2H, -CH2), 3.977(t, 2H, -CH2), 3.738(d, 2H, J=8.04, POCH2), 1.338-
1.256(m, 12H, 4x-CH3) 
13C NMR (CDCl3): 164.22, 159.49, 149.58, 143.0, 115.73, 71.26, 71.19, 66.86, 65.2, 
23.92 
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IR (KBr Pellet): 3408.9(-NH2 stretching), 2923.9(-CH2 stretching), 1598.9(C=C 
stretching), 1545(N-H stretching), 1357.8(C-N stretching, Aromatic), 1300.9(POOiPr2), 
1194.8(C-N stretching, Aliphatic), 1107.1(C-O stretching), 985.6(P-O-C stretching), 
807.2(oop bending) 
MS (EI, m/z): 391(M+, 2), 212(14), 197(19), 195(5), 169(22), 160(6), 149(13), 139(79), 
125(29), 110(14), 97(63), 82(13), 65(16), 43(100), 41(35). 
Anal. Calc.: C 42.90%, H 5.92%, N 17.88%; Anal. Observed: C 42.97%, H 5.95%, N 
85%.  
 
 
Synthesis of 7 and 9-isomers… 
 
83
6. SPECTRA OF THE REPRESENTATIVE COMPOUNDS 
1H NMR Spectra of ATM 102-104 
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1H NMR Spectrum of ATM-200 
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13C NMR Spectrum of ATM-200 
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EI-MS Spectrum of ATM-200 
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1H NMR Spectrum of ATM-300  
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13C NMR Spectrum of ATM-300 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEPT-135 Spectrum of ATM-300 
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EI-MS Spectrum of ATM-300 
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FT-IR Spectrum of ATM-200  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FT-IR Spectrum of ATM-300 
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1. THE CONCEPT OF PROTIDES (PRONUCLEOTIDES) 
 
Phosphonate Masking Pro-drug Strategies 
 
(S)-HPMPA [(S)-9-(3-hydroxy-2-phosphonomethoxypropyl)-adenine] was the first 
acyclic nucleoside phosphonate to show potent, broad-spectrum antiviral activity. 
Described by Holy´ and De Clerq in 1986, [1] (S)-HPMPA inhibits replication of many 
double-stranded DNA viruses, including herpes simplex virus (HSV) types 1 and 2, 
varicella zoster virus (VZV), thymidine kinase-deficient (TK-) mutants of HSV and VZV, 
human cytomegalovirus (HCMV), Epstein-Barr virus, hepatitis B virus, adenoviruses, 
and various  orthopoxviruses. [2] (S)-HPMPA also arrests the growth of Plasmodium 
falciparum (the causative agent of malaria)[3] and exhibits cytostatic activity against 
L1210 mouse leukemia cells in vitro. [4] After the discovery of (S)-HPMPA, extensive 
studies of acyclic nucleoside phosphonates led to the development of three licensed 
antivirals scidofovir (CDV; CMV retinitis), adefovir (hepatitis B), and tenofovir 
(HIV/AIDS)[5] and the identification of many more compounds with potentially useful 
biological activity. [6] However, due to the presence of two negative charges, free acyclic 
nucleoside phosphonates are not absorbed well orally. [7] After intravenous injection, 
drugs of this class accumulate in the kidney, the site of dose-limiting toxicity. [8] CDV 
(Vistide) is administered intravenously, while the oral formulations of adefovir (Hepsera) 
and tenofovir (Viread) are the bispivaloyloxymethyl and bis-(isopropoxycarbonyl) 
oxymethyl esters, respectively. [9,10] There is considerable interest in phosphonates as 
biologically active mimics of natural phosphonates. Phosphonate replacement is 
attractive, since the carbon-phosphorous bond is not susceptible to enzymatic cleavage by 
phosphonates, thus enhancing physiological stability. Moreover, the presence of α-
phosphonate allows circumventing the often rate-limiting step. [12] 
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Several other phosphonate-masking prodrug strategies, including aryl phosphona- 
midates [11] and cyclosal esters,[12] have been applied to acyclic nucleoside 
phosphonate. 
Illustration of some PRONUCLEOTIDE (ProTides) 
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N
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N
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Where R=3-hexadecyclo-1-propanol
                  2-octadecyclooxy-1-ethanol
                  2-oleyloxy-1-ethanol
                  3-oleyloxy-1-propanol
                                 Prodrug of (S)-HPMPA
 
N
N N
N
NH2
Prodrugs of PMEA
(H) i-Pr O
P
O
OiPr
OiPr
 
N
N N
N
O
Prodrugs of PMEG
H2N O
P
O
OiPr
OiPr
 
 
 
Small Library from 9-isomer… 95
 
O
HO
O OHO
H3NCl
Me
N
N
NH3
O
Cl
2'-C-Methylcytidine dihydrochloride
   Prodrug of 2'-C-Methylcytidine  
Instead of Acyclic Phosphonate Nucleoside (APN), several other side chains are also 
reported at 9-position of the purine and 6-position of the adenine. Some of the side chains 
are enlisted below. 
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2. REACTION SCHEME 
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Where R = Various bases like
                  Pyrrolidine, Morpholine
                  Cyclohexylamine etc.
ATM 300
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3. EXPERIMENTAL PROTOCOL 
 
To a stirred solution of ATM 300 (500mg, 1eq) in acetonitrile (20 ml) base (1.2-2eq) was 
added in a dropwise manner. After the completion of addition of base, the reaction 
mixture was heated to reflux for appropriate time. The reactions were monitored by TLC 
(Chloroform:Methanol). After the completion of reaction, acetonitrile was stripped off in 
vacuo, leaves the crude product. Resulting crude product was extracted with ethyl acetate, 
washed with brine and dried over sodium sulphate. The solvent was removed in vacuo, 
leaves the crude product. Finally, it was purified by silica gel column chromatography 
(60-100 mesh) using chloroform and methanol as eluents. 
All the compounds of the series ATM 301 to ATM 329 were synthesized by above 
procedure. All the physical data of the compounds were found in Table 2. 
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4. STRUCTURES OF COMPOUNDS SYNTHESIZED UNDER THIS 
SERIES (ATM 301-329) 
Code Scaffold Code Scaffold 
ATM 301 
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N N
N
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N
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O O
O
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N N
N
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P
O O
O
O
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N N
N
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N
O
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O O
O
N
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ATM 304 
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N N
N
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NH
O
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O O
O
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O O
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O
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O O
O
 
ATM 307 
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ATM 309 
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ATM 317 
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ATM 325 
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5. TABLE 2: PHYSICAL DATA 
 
Code No. MF/MW Physical Appearance Mp/
oC TLC (C:M)/Rf 
Time/ 
%Yields 
ATM 301 C18H31N6O4P/426.45 White solid 112-114 8.0:2.0/0.295 4:30/65 
ATM 302 C18H31N6O5P/442.45 White solid 110-112 9.0:1.0/0.358 2:00/85 
ATM 303 C19H34N7O4P/455.49 Oily liquid - 9.0:1.0/0.299 3:30/63 
ATM 304 C20H35N6O4P/454.50 Oily liquid - 8.0:2.0/0.452 2:50/69 
ATM 305 C24H34N7O4P/515.55 White solid 142-144 9.2:0.8/0.369 3:40/78 
ATM 306 C17H31N6O4P/414.44 Oily liquid - 9.5:0.5/0.388 3:30/69 
ATM 307 C19H33N6O4P/440.48 Yellow solid 96-98 9.0:1.0/0.285 4:05/55 
ATM 308 C18H31N7O4P/440.46 Oily liquid 168-170 9.2:0.8/0.288 3:30/85 
ATM 309 C18H33N6O4P/428.47 White solid 104-106 9.0:1.0/0.350 1:00/79 
ATM 310 C20H30N7O4P/463.47 Oily liquid - 9.5:0.5/0.300 5:30/59 
ATM 311 C19H34N7O4P/471.49 Oily liquid - 9.0:1.0/0.258 6:30/51 
ATM 312 C25H38N7O4P/531.59 White solid 95-96 9.0:1.0/0.422 4:15/67 
ATM 313 C16H30N7O4P/415.43 Oily liquid - 9.5:0.5/0.498 4:40/71 
ATM 314 C18H32N7O5P/457.46 Oily liquid - 9.2:0.8/0.331 7:15/58 
ATM 315 C19H35N8O4P/470.51 White solid 117-118 9.5:0.5/0.412 5:00/69 
ATM 316 C19H33N6O4P/440.48 Oily liquid - 9.0:1.0/0.315 6:15/55 
ATM 317 C21H31N6O4P/462.48 Yellow solid 94-96 9.0:1.0/0.369 9:55/81 
ATM 318 C16H27N6O6P/430.40 Oily liquid - 9.0:1.0/0.358 4:40/58 
ATM 319 C18H33N6O5P/444.47 White solid 115-116 9.0:1.0/0..377 3:15/68 
ATM 320 C24H36N7O4P/517.56 White solid 100-102 9.5:0.5/0.285 1:45/72 
ATM 321 C20H36N7O4P/469.52 Oily liquid - 9.0:1.0/0.250 4:05/65 
ATM 322 C17H32N7O4P/429.45 White solid 119-120 9.0:1.0/0.400 2:20/69 
ATM 323 C16H29N6O4P/484.57 Oily liquid - 9.5:0.5/0.412 4:15/63 
ATM 324 C20H37N6O4P/456.52 Oily liquid - 9.8:0.2/0.300 8:30/68 
ATM 325 C17H31N6O4P/414.44 Yellow  solid 110-112 9.8:0.2/0.297 9:50/78 
ATM 326 C18H33N6O4P/428.47 White solid 92-94 9.5:0.5/0.290 4:55/86 
ATM 327 C18H27N6O5P/438.42 Oily liquid - 9.5:0.5/0.233 8:30/78 
ATM 328 C16H29N6O4P/400.41 Oily liquid - 9.2:0.8/0.331 7:15/61 
ATM 329 C14H25N6O5P/388.36 Oily liquid - 9.0:1.0/0.318 5:55/55 
 
MF=Molecular Formula 
MW=Molecular Weight 
C:M=Chloroforom:Methanol
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6. SPECTRAL DISCUSSION 
1H NMR Spectra 
Proton NMR spectra were recorded on Bruker 300 and 400MHz (Avance-II) instruments 
using CDCl3 and D2O as the solvents with tetramethylsilane (TMS) as the respective 
internal standard. Chemical shifts were recorded in (δ) and coupling constants were 
recorded in Hertz (J). Number of protons found in NMR is concomitant with the 
theoretical value. The presence of the isopropyl group is confirmed by the splitting 
pattern doublet-multiplet. The H-8 proton is observed in between 7.58-7.61 in all the 
spectra. The position of the –NH2 group present at 2-position is vary around ~4.9-5.5 δ. In 
some of the spectra, it merges with the multiplet. Two triplets were observed at ~4 and ~3 
δ which is of presence of two methylene groups in the structure, corresponding to 
electronegativity of the nitrogen and oxygen, the methylene group which is adjacent to 
“O” shows more downfield as compared to “N”. One more methylene group adjacent to 
“P”, present in the aliphatic side chain shows characteristic doublet having coupling 
constant ~8. The chemical shifts of the various bases at position-6, changes depending 
upon the type of substitution taken place. One more remarkable observation is that, the 
protons of the bases at 6-position is not clearly splitted, according to theoretical splitting 
pattern.  
13 C NMR Spectra 
13C NMR spectra were recorded on Bruker 400MHz instruments using DMSO-d6 and 
CHCl3 as the solvents with tetramethylsilane (TMS) as the respective internal standard. 
The chemical shifts were recorded in (δ). Numbers of carbon present in the purine 
molecules investigate are comparable with the experimental and 13C spectral evidences. 
The quaternary carbon at position-2 of the purine moiety, attached between two nitrogen 
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of the pyrimidine ring and –NH2 appears at the most downfield in the spectrum (~159-
160 δ).  
DEPT-135 
The presence of three methylene group, four methyl group and methine carobon in the 
purine core structure was confirmed by DEPT-135 experiment. The methylene group (-
CH2) was found at downwards while methyl and methine group (-CH3 and –CH)  was 
found in the upward direction with respect to solvent. The presence of C-8 carbon shows 
at ~140 δ. The spectral pattern is varying depending upon the type of substitution at 
position-6. One methylene group, adjacent to the “P” atom, splitted in to doublet in the 
CMR spectra, splitting of this carbon into doublet strongly indicate that the methylene 
group is attached with the P-atom of the purine core structure. 
FT-IR Spectra 
IR spectra were recorded on Shimadzu FTIR-8400 using KBr disc and DRS techniques. 
The percentage transmittance is given in cm-1. The presence of 1o-Amine and 2o-Amine 
was confirmed at ~3300 as doublet and singlet. In the aromatic C=C stretching is 
observed at ~1650. The C-H stretching is observed at ~2950. N-H stretching is observed 
at ~1580. Characteristic P=O stretching is observed at ~1550. C-N, aromatic and aliphatic 
is stretched at ~1350 and ~1250 respectively. The C-O stretching of the aliphatic ether is 
observed at ~1100. Rests of the spectral information are given in the spectral data. 
Mass spectra 
Mass spectra were recorded on Shimadzu GCMS-QP2010 by EI technique. In all the 
compound the molecular ion peak and base peak are different. Different fragmentation 
pattern is seen in synthesized compounds. 
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Elemental Analysis 
Elemental analysis of the compounds was carried out on Elementar Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned.   
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7. SPECTRAL DATA 
Diisopropyl (2-(2-amino-6-pyrolidine-1-yl)-9H-purine-9-yl) ethoxy) methyl 
phosphonate (ATM 301) 
MS (EI, m/z): 426(M+, 19), (M+1, 5), 411(2), 384(0.2), 369(2), 341(8), 325(7), 293(2), 
261(7), 247(68), 232(69), 219(15), 204(44), 190(18), 177(22), 163(7), 149(8), 135(15), 
123(11), 108(10), 95(10), 70(30), 65(7), 43(100), 41(36). 
Anal. Calc.: C 50.70%, H 7.33%, N 19.71%; Anal. Observed: C 50.66%, H 7.33%, N 
19.68%.  
Diisopropyl (2-(2-amino-6-morpholino)-9H-purine-9-yl) ethoxy) methyl 
phosphonate (ATM 302) 
1H NMR (CDCl3): δ 7.596(s, 1H, H-8), 4.728-4.680(m, 2H, 2x-CH), 4.654(brs, 2H, -
NH2), 4.231(t, 6H, -CH2), 3.887(t, 2H, -CH2), 3.801(t, 4H, -CH2), 3.715(d, 2H, J=8.4, 
POCH2), 1.313(d, 6H, 2x-CH3), 1.280(d, 6H, 2x-CH3). 
13C NMR (CDCl3): δ 159.14, 154.29, 152.97, 137.26, 114.71, 71.33, 71.23, 71.18,  
67.09, 66.88, 65.22, 24.07, 24.04, 24.01, 23.96. 
IR (KBr Pellet): 3396.76 & 3335.03(1°-NH2), 3223.16(=CH), 2976.26(C-H), 
1645.33(C=C), 1583.61(N-H), 1356.00(C-N, Aromatic), 1251.84(C-N, Aliphatic), 
1174(P=O), 1109.11(C-O), 852.56(P-O), 829.42(oop bending). 
MS (EI, m/z): 442(M+, 39), 444(M+1, 8), 427(8), 412(14), 397(5), 385(7), 369(5), 
357(9), 341(10), 327(9), 313(10), 301(9), 283(0.5), 277(10), 263(100), 248(85), 233(37), 
217(53), 203(43), 190(25), 175(12), 163(20), 149(5), 135(28), 123(12), 108(15), 95(15), 
80(17), 56(13), 43(81), 41(26). 
Anal. Calc.: C 48.86%, H 7.06%, N 18.99%; Anal. Observed: C 48.88%, H 7.06%, N 
18.95%.  
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Diisopropyl (2-(2-amino-6-(4-methylpiperazine-1-yl)-9H-purine-9-yl) ethoxy) 
methyl phosphonate (ATM 303) 
1H NMR (CDCl3): 7.583(s, 1H, H-8), 4.746-4.661(m, 2H, 2x-CH), 4.626(brs, 2H, -NH2), 
4.221(t, 2H, -CH2), 3.879(t, 2H, -CH2), 3.7(d, 2H, J=6, POCH2), 2.51(t, 5H), 2.336(s, 3H, 
-CH3), 2.190(brs, 3H), 1.316-1.261(q, 12H, 4x-CH3). 
MS (EI, m/z): 455(M+, 33), (M+1, 9), 440(13), 412(4), 398(7), 385(100), 372(40), 
354(6), 343(49), 327(2), 313(2), 301(87), 283(12), 276(4), 253(4), 239(1), 233(11), 
219(14), 205(10), 193(18), 178(49), 163(22), 150(6), 135(18), 123(4), 108(10), 95(11), 
70(18), 56(11), 43(60), 41(15). 
Anal. Calc.: C 50.10%, H 7.52%, N 21.53%; Anal. Observed: C 50.11%, H 7.55%, N 
21.50%.  
Diisopropyl (2-(6-cyclohexylamino)-2-amino-9H-purine-9-yl) ethoxy) methyl 
phosphonate (ATM 304) 
1H NMR (CDCl3): 7.578(s, 1H, H-8), 5.518(brs, 1H, -NH), 4.862(brs, 2H, -NH2), 4.748-
4.662(m, 2H, 2x-CH), 4.214(t, 2H, -CH2), 4.198(s, 1H, -CH), 3.883(t, 2H, -CH2), 
3.719(d, 2H, J=8.31, -POCH2), 2.05(d, 2H, -CH2), 1.776-1.618(m, 4H), 1.473-1.264(m, 
16H). 
13C NMR (CDCl3): 160.41, 154.97, 152.25, 138.26, 114.55, 71.81, 71.67, 71.55, 67.15, 
65.29, 61.84, 43.24, 33.78, 26.01, 25.28, 24.42, 24.36, 24.29, 15.62. 
Diisopropyl (2-(6-(2-(1H-indole-3-yl)ethylamino)-2-amino-9H-purine-9-yl) 
ethoxy) methylphosphonate (ATM 305) 
1H NMR (CDCl3): 8.397(brs, 1H, -NH), 7.67(d, 1H, J=8, Ar-H), 7.518(s, 1H, -CH), 
7.381(d, 1H, J=8, Ar-H), 7.284(s, 1H, Ar-H), 7.210(t, 1H, Ar-H), 7.134(t, 1H, Ar-H), 
7.117(s, 1H), 7.049(d, 1H, -CH), 5.8(s, 1H, NH), 4.736-4.686(m, 4H, -CH2 & -NH2),  4. 
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207(t, 2H, -CH2), 3.905(t, 4H, -CH2), 3.72(d, 2H, J=6.8, POCH2), 3.116(t, 2H, -CH2), 
1.326-1.212(m, 12H, 4x-CH3). 
13C NMR (CDCl3): δ 160.00, 155.30, 138.09, 136.49, 127.39, 122.23, 121.95, 119.22, 
118.79, 112.95, 111.29, 71.42, 71.28, 71.21, 66.87, 65.20, 42.91, 24.07, 24.03, 24.00, 
23.95. 
IR (KBr Pellet): 3556.85(1°-NH2), 3460.46(2°-NH2), 2978.19(=CH), 1633.76(C=C), 
1599.04(N-H), 1356.00(C-N, Aromatic), 1251.84(C-N, Aliphaitc), 1211.34(P=O), 
1120.68(C-O), 792.77(P-O).  
MS (EI, m/z): 515(M+, 4), 386(2), 373(68), 343(1), 331(11), 301(16), 289(22), 219(4), 
207(10), 193(29), 178(58), 163(16), 150(19), 130(20), 115(0.5), 103(4), 95(8), 77(6), 
65(3), 44(98), 41(31).  
Anal. Calc.: C 55.91%, H 6.65%, N 19.02%; Anal. Observed: C 55.95%, H 6.69%, N 
19.0%.  
Diisopropyl (2-(2-amino-6-(isopropylamino)-9H-purine-9-yl) ethoxy) methyl 
phosphonate (ATM 306) 
MS (EI, m/z): 414(M+, 25), 415(M+1, 6), 399(7), 391(5), 371(2), 357(7), 329(8), 
315(13), 297(4), 290(3), 267(4), 249(5), 235(85), 220(100), 205(67), 193(22), 178(43), 
163(19), 150(29), 135(32), 123(11), 108(13), 95(16), 80(5), 58(50), 43(85), 41(47). 
Anal. Calc.: C 49.27%, H 7.54%, N 20.28%; Anal. Observed: C 49.29%, H 7.56%, N 
20.26%.  
Diisopropyl (2-(2-amino-6-(piperidine-1-yl)-9H-purine-9-yl)ethoxy) methyl 
phosphonate (ATM 307) 
1H NMR (CDCl3): δ 7.576(s, 1H, H-8), 4.781(s, 2H, -NH2), 4.736-4.656(m, 3H, 2x-CH), 
4.293-4.157(m, 5H, -CH2), 3.927-3.872(m, 3H, -CH2), 3.729(d, 2H, -POCH2), 1.657(m, 
5H, 2x-CH2), 1.306(d, 6H, 2x-CH3), 1.272(d, 6H, 2x-CH3).  
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13C NMR (CDCl3): δ 159.13, 152.60, 143.13, 136.62, 114.47, 71.3, 71.19, 71.1, 66.78, 
65.12, 46.02, 43.31, 42.85, 26.09, 24.84, 23.98, 23.95, 23.90. 
IR (KBr Pellet): 3336.96(1°-NH2), 3217.37(=CH), 2976.26(C-H), 1645.33(C=C), 
1568.18(N-H), 1371.43(C-N, Aromatic), 1278.85(C-N, Aromatic), 1188.19(P=O), 
1101.39(C-O), 941.29(P-O). 
MS (EI, m/z): 440(M+, 23), 441(M+1, 5), 425(4), 411(0.5), 397(4), 383(4), 365(1), 
355(16), 339(8), 327(2), 309(3), 301(4), 287(0.5), 275(7), 261(93), 246(100), 231(6), 
218(16), 203(12), 190(30), 178(22), 163(12), 149(6), 135(16), 123(7), 108(8), 84(19), 
83(5), 56(6), 43(33), 41(18). 
Anal. Calc.: C 51.81%, H 7.55%, N 19.08%; Anal. Observed: C 51.83%, H 7.56%, N 
19.05%.  
Diisopropyl (2-(2-amino-6-(pipeazine-1-yl)-9H-purine-9-yl)ethoxy)methyl 
phosphonate (ATM 308) 
1H NMR (CDCl3): δ 7.616(s, 1H, H-8), 4.807(s, 2H, -NH2), 4.760-4.664(m, 2H, 2x-CH), 
4.341(brs, 8H, 4x-CH2), 4.238(t, 2H, -CH2), 3.892(t, 2H, -CH2), 3.726(d, 2H, J=8.28, -
CH2), 1.322-1.275(q, 12H, 4x-CH3). 
13C NMR (CDCl3): 159.19, 154.27, 152.90, 137.16, 114.72, 71.34, 71.23, 71.18, 66.84, 
65.17, 45.05, 42.88, 24.05, 24.01, 23.98, 23.94. 
Anal. Calc.: C 48.97%, H 7.31%, N 22.21%; Anal. Observed: C 48.99%, H 7.30%, N 
22.18%.  
Diisopropyl (2-(2-amino-6-(diethylamino)-9H-purine-9-yl) ethoxy) methyl 
phosphonate (ATM 309) 
1H NMR (CDCl3): δ 7.574(s, 1H, H-8), 4.781(brs, 2H, -NH2), 4.722-4.641(m, 2H, 2x-
CH), 4.219(t, 2H, -CH2), 3.923-3.872(m, 6H, 3x-CH2), 3.716(d, 2H, J=8.32, -POCH2), 
1.308-1.223(m, 18H, 6x-CH3). 
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13C NMR (CDCl3): δ 159.28, 154.08, 152.43, 136.85, 114.36, 71.35, 71.24, 71.11, 
66.79, 65.13, 42.80, 42.47, 24.00, 23.97, 23.92, 23.88, 13.52. 
IR (KBr Pellet): 3406.40 & 3333.10(1º-NH2), 3230.87(2º-NH2), 2978.19(=CH), 
1643.41(C=C), 1579.75(N-H), 1377.12(C-N, Aromatic), 1249.91(C-N, Aliphatic), 
1178.55(P=O), 1141.09(C-O), 891.14(P-O). 
MS (EI, m/z): 428(M+, 45), 429(M+1, 22), 413(10), 399(18), 385(9), 371(5), 357(14), 
343(15), 327(11), 315(52), 301(16), 281(2), 267(3), 263(9), 249(20), 234(61), 219(20), 
205(26), 191(100), 177(21), 163(29), 150(6), 135(24), 123(14), 108(11), 95(12), 72(14), 
65(6), 43(74), 41(18). 
Anal. Calc.: C 50.46%, H 7.76%, N 19.61%; Anal. Observed: C 50.48%, H 7.76%, N 
19.58%.  
Diisopropyl (2-(2-amino-6-(benzylamino)-9H-purine-9-yl) ethoxy) methyl 
phosphonate (ATM 317) 
1H NMR (CDCl3): δ 7.516(s, 1H, H-8), 7.339-7.234(m, 5H, Ar-H), 6.293(brs, 1H, -NH), 
4.932(s, 2H, -CH2), 4.775(brs, 2H, -NH2), 4.712-4.662(m, 2H, 2x-CH), 4.188(t, 2H, -
CH2), 3.866(t, 2H, -CH2), 3.707(d, 2H, J=8.32, -POCH2), 1.303-1.253(m, 12H, 4x-CH3).  
13C NMR (CDCl3): δ 159.97, 155.09, 151.10, 138.95, 138.17, 128.15, 127.64, 127.21, 
114.18, 71.34, 71.23, 71.17, 66.78, 65.11, 42.86, 24.02, 23.98, 23.95, 23.90. 
IR (KBr Pellet): 3497.06(2o-NH2), 3284.88(1º-NH2), 3184.58(=CH), 2980.12(C-H), 
1626.05(C=C), 1585.54(N-H), 1373.36(C-N, Aromatic), 1271.13(C-N, Aliphatic), 
1178.55(P=O), 1120.68(C-O), 910.43(P-O). 
MS (EI, m/z): 462(M+, 18), 461(M+1, 6), 447(3), 419(5), 405(3), 378(8), 377(15), 
361(5), 329(4), 297(4), 283(37), 268(4), 253(4), 240(21), 223(3), 206(2), 193(3), 178(5), 
163(23), 150(4), 135(18), 123(8), 106(36), 91(100), 79(8), 65(11), 43(44), 41(13). 
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Anal. Calc.: C 54.54%, H 6.76%, N 18.17%; Anal. Observed: C 54.56%, H 6.8%, N 
18.14%.  
Diisopropyl (2-(2-amino-6-(2-amino-butane-1-ol)-9H-purine-9-yl) ethoxy) 
methyl phosphonate (ATM 319) 
MS (EI, m/z): 444(M+, 40), (M+1, 24), 427(10), 414(58), 399(41), 391(42), 371(15), 
357(8), 343(9), 329(47), 315(7), 308(2), 290(11), 266(4), 265(18), 250(11), 225(12), 
212(60), 197(100), 196(48), 169(71), 160(20), 150(5), 139(48), 123(19), 106(5), 97(45), 
80(5), 65(10), 43(100), 41(33).  
Anal. Calc.: C 48.64%, H 7.48%, N 18.91%; Anal. Observed: C 48.67%, H 7.52%, N 
18.85%.  
Diisopropyl (2-(2-amino-6-(4-phenylpiperazine-1-yl)-9H-purine-9-yl)ethoxy) 
methyl phosphonate (ATM 320) 
1H NMR (CDCl3): δ 7.612(s, 1H, H-8), 7.302-7.262(m, 2H, Ar-H), 6.965(d, 2H, Ar-H), 
6.886(t, 1H, Ar-H), 4.786(brs, 2H, -NH2), 4.724-4.674(m, 2H, 2x-CH), 4.386(brs, 4H), 
4.227(t, 2H, -CH2), 3.883(t, 2H, -CH2), 3.713(d, 2H, J=8.24, -POCH2), 3.273(t, 4H), 
1.315-1.258(m, 12H, 4x-CH3).  
13C NMR (CDCl3): δ 159.22, 154.14, 152.92, 151.29, 137.15, 129.14, 120.11, 116.42, 
114.65, 71.34, 71.17, 71.11, 66.86, 65.19, 49.60, 44.76, 42.91, 24.08, 24.04, 24.01, 23.96. 
IR (KBr Pellet): 3392.9 & 3333.1(1o –NH2), 3223.16(=CH), 2976.26(C-H), 
1643.41(C=C), 1570.11(N-H), 1348.29(C-N, Aromatic), 1242.28(C-N, Aromatic), 
1153.47(P=O), 1101.39(C-O),  833.28(P-O), 786.98(N-H, opp). 
MS (EI, m/z): 517(M+, 6), 516(M+1, 3), 502(4), 487(1), 473(1), 459(2), 427(1), 416(1), 
399(2), 385(12), 372(13), 337(41), 322(10), 309(1), 301(7), 283(1), 267(1), 260(1), 
247(7), 231(5), 218(28), 205(100), 192(8), 177(4), 163(52), 147(3), 139(20), 120(55), 
104(18), 91(14), 77(24), 56(16), 42(55), 41(78). 
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Anal. Calc.: C 55.70%, H 7.01%, N 18.94%; Anal. Observed: C 55.75%, H 7.07%, N 
18.89%.  
Diisopropyl (2-(6-(3-aminopropylamino)-2-amino-9H-purine-9-yl)ethoxy) 
methyl phosphonate (ATM 322) 
1H NMR (CDCl3): δ 7.601(s, 1H, H-8), 7.305(brs, 1H, -NH), 5.644(brs, 2H, -NH2, 
4.756-4.661(m, 2H, 2x-CH), 4.231(t, 2H, -CH2), 3.889(t, 2H, -CH2), 3.8(d, 2H, J=8, -
POCH2), 3.743-3.641(brs, 2H, -CH2), 3.033(s, 1H), 1.78(brs, 1H), 1.317-1.2702(m, 14H) 
13C NMR (CDCl3): δ 160.46, 155.61, 150.76, 137.81, 114.10, 71.33, 71.20, 71.14, 66.82, 
65.15, 42.86, 35.69, 29.93, 24.05, 24.01, 23.97, 23.93 
IR (KBr Pellet): 3585.79(1º-NH2), 3444.98(2º-NH2), 2978.19(C-H), 1595.18(N-H), 
1371.41(C-N, Aromatic), 1247.99(C-N, Aliphatic), 1176.62(P=O), 1120.68(C-O). 
MS (EI, m/z): 429(M+,1.2), 420(3), 408(3), 399(8), 386(8), 373(4), 352(4), 336(2), 
334(5), 315(7), 301(3), 290(8), 272(2), 260(6), 245(5), 226(8), 212(40), 197(54), 193(13), 
169(56), 160(22), 150(13), 139(44), 123(15), 106(6), 97(37), 82(7), 65(14), 54(10), 
43(100). 
Anal. Calc.: C 47.54%, H 7.51%, N 22.83%; Anal. Observed: C 47.58%, H 7.55%, N 
22.80%.  
Diisopropyl (2-(2-amino-6-(octylamino)-9H-purine-9-yl) ethoxy) methyl 
phosphonate (ATM 323) 
MS (EI, m/z): 484(M+50), 485(M+1, 35), 469(11), 455(4), 441(7), 427(7), 413(3), 
399(22), 386(10), 371(4), 357(8), 343(4), 329(3), 315(15), 305(100), 290(100), 275(4), 
262(8), 247(15), 233(13), 219(12), 205(18), 192(33), 178(63), 163(18), 150(20), 135(20), 
123(8), 108(6), 95(8), 81(2), 71(3), 57(5), 43(45), 41(13).  
Anal. Calc.: C 54.53%, H 8.53%, N 17.34%; Anal. Observed: C 54.56%, H 8.55%, N 
17.30%. 
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Diisopropyl (2-(2-amino-6-(propylamino)-9H-purine-9-yl)ethoxy) methyl 
phosphonate (ATM 325) 
1H NMR (CDCl3): δ 7.589(s, 1H, H-8), 5.744(brs, 1H, -NH), 4.936(brs, 2H, -NH2), 
4.739-4.659(m, 2H, 2x-CH), 4.221(t, 2H, -CH2), 3.891(d, 2H, -CH2), 3.744-3.7153(q, 2H, 
J=8.32, -POCH2), 3.536(brs, 2H, -CH2), 1.677-1.604(m, 2H), 1.350-1.240(m, 12H), 
0.977(t, 3H, -CH3). 
13C NMR (CDCl3): δ 159.96, 155.34, 143.12, 137.93, 114.15, 71.36, 71.25, 71.13, 66.79, 
65.13, 42.85, 24.00, 23,97, 23.93, 23.89, 22.98, 11.36 
IR (KBr Pellet): 3294.53(1º-NH2), 3182.85(2º-NH2), 3095.85(=CH), 2983.98(C-H), 
1645.33(C=C), 1593.25(N-H), 1369.50(C-N, Aromatic), 1280.78(C-N, Aliphatic), 
1176.62(P=O), 1169.11(C-O), 910.43(P-O). 
MS (EI, m/z): 414(M+, 35), 415(M+1, 11), 399(13), 391(3), 371(1), 357(10), 343(2), 
315(11), 301(10), 283(4), 267(1), 253(1), 249(7), 235(100), 220(86), 205(12), 191(35), 
178(54), 163(15), 150(27), 135(17), 123(7), 108(6), 95(10), 82(2), 65(4), 43(40), 41(13). 
Anal. Calc.: C 49.27%, H 7.54%, N 20.28%; Anal. Observed: C 49.30%, H 7.55%, N 
20.26%.  
Diisopropyl (2-(2-amino-6-(butylamino)-9H-purine-9-yl)ethoxy) methyl 
phosphonate (ATM 326) 
1H NMR (CDCl3): δ 7.584(s, 1H, H-8), 5.635(brs, 1H, -NH), 4.902(brs, 2H, -NH2), 
4.741-4.660(m, 2H, 2x-CH), 4.218(t, 2H, -CH2), 3.890(t, 2H, -CH2), 3.723(d, 2H, J=8.32, 
-POCH2), 3.565(brs, 2H), 1.640-1.567(q, 2H, -CH2), 1.458-1.366(m, 2H, -CH2), 1.316-
1.268(q, 12H, 4x-CH3), 0.932(t, 3H, -CH3). 
13C NMR (CDCl3): δ 160.46, 155.61, 150.76, 137.82, 114.10, 71.44, 71.34, 71.21, 66.82, 
65.16, 42.85, 31.85, 24.06, 24.02, 23.98, 23.94, 19.97, 13.76. 
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IR (KBr Pellet): 3302.24(1º-NH2), 3190.37(2º-NH2), 3095.85(=CH), 2983.98(C-H), 
1647.26(C=C), 1593.25(N-H), 1369.5(C-N, Aromatic), 1284.63(C-N, Aliphatic), 
1176.62(P=O), 1109.11(C-O), 941.29(P-O).   
MS (EI, m/z): 428(M+, 30), 429(M+1, 18), 413(8), 399(7), 385(4), 371(5), 357(4), 
343(8), 327(9), 315(15), 301(9), 283(4), 267(2), 263(8), 249(100), 234(75), 219(7), 
205(24), 191(32), 178(46), 163(14), 150(21), 135(18), 123(8), 108(6), 95(8), 82(2), 57(3), 
43(32), 41(11). 
Anal. Calc.: C 50.46%, H 7.76%, N 19.61%; Anal. Observed: C 50.49%, H 7.80%, N 
19.59%.  
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8. SPECTRA OF THE REPRESENTATIVE COMPOUNDS 
1H NMR Spectrum of ATM-302 
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13C NMR Spectrum of ATM-302 
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DEPT-135 Spectrum of ATM-302 
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EI-MS Spectrum of ATM-302 
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1H NMR Spectrum of ATM-305 
(Little solvent impurity i.e. Ether is found in the Spectrum, but it ractified in the CMR 
spectrum) 
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13C NMR and DEPT-135 Spectra of ATM-305 
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EI-MS Spectrum of ATM-305 
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1H NMR Spectrum of ATM-309 
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13C NMR and DEPT-135 Spectra of ATM-309 
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1H NMR Spectrum of ATM-317 
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13C NMR and DEPT-135 Spectra of ATM-317 
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1H NMR Spectrum of ATM-320 
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13C NMR and DEPT-135 Spectra of ATM-320 
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1. INTRODUCTION 
 
The synthetic chemistry of purine analogs already discussed in details in first chapter of 
introduction and also the exploratory work on 9-isomer is covered in third chapter. In 
continuation of this, the current chapter covers the chemistry of 7-isomer not explored so 
far. Even if it is biologically inactive then it is also difficult to find some negative results 
and literature references too. In current work, we explore 6-position of the 7-isomer by 
replacing chlorine group by various bases like primary or secondary amines. This is our 
novel approach of the current work. In fact, It is difficult to replace chlorine at 6-position 
in 7-isomer than 9-isomer. Steric interaction with the phosphorylated side chain and 
incoming base i.e 1o or 2o amine may be the reason and the rate of reaction is also 
sluggish, in spite of this fact the efforts have been made to explore the 6-positon in 
various reaction conditions.  
ATM 200 (7-isomer) is not easily soluble in acetonitrile, so we also carry out reaction in 
DMF (Dimethyl formamide). In DMF, reaction proceeds smoothly but it is difficult to 
isolate the products from DMF in most of the cases. While in case of acetonitrile it is easy 
to isolate the products. Ultimately, all the reactions were carried out in excess acetonitrile, 
even though the rate of reaction is sluggish. The replacement of 6-position of purine by 
means of various bases are itself novel. Position-6 is replaced by various aromatic 1o 
amines and some of the acyclic 1o or 2o amines by Liu, H. et al. [1]   
Some authors placed only –NH2 functionality at 6-position. 6-positon is also replaced by 
guanidine functionality is reported by Cesnek M. et al. [2]  
References: 
[1] Huang, H.; Liu, H.; Chen, K.; Jiang, H.; J. Comb. Chem. 2007, 9, 197-199. 
[2] Cesnek, M.; Holy, A.; Masojidkova, M. Tetrahedron 2002, 58, 2985-2996.
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2. REACTION SCHEME 
Acetonitrile/Base
Reflux
Where R = Various bases like
                  Pyrrolidine, Morpholine
                  Cyclohexylamine etc.
N
N N
N
Cl
H2N
O
PO
O
O
N
N N
N
R
H2N
O
PO
O
O
ATM 200
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3. EXPERIMENTAL PROTOCOL 
 
To a stirred solution of ATM 200 (500mg, 1eq) in acetonitrile (15 ml), base (2eq-10eq) 
was added in a dropwise manner. After the completion of addition of base, the reaction 
mixture was heated to refluxed for an appropriate time. The reaction was monitored by 
TLC (Chloroform: Methanol). After the completion of reaction, acetonitrile was stripped 
off in vacuo, leaves the crude product. To the crude reaction mixture, ethyl acetate or 
MDC was added, washed with brine and dried over sodium sulphate. The solvent was 
removed in vacuo, leaves the crude product. Finally, it was purified by silica gel column 
chromatography (60-100 mesh) using chloroform and methanol as eluents. 
All the compounds of the series ATM 201 to ATM 229 were synthesized by above 
procedure. All the physical data of the compounds were found in Table 3. 
? The reaction was also proceeding in DMF in short time than acetonitrile, but 
isolation of the product from DMF is difficult. 
? The reaction mixtures were turned into green after the completion of the 
reaction. 
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4. STRUCTURES OF COMPOUNDS SYNTHESIZED UNDER THIS 
SERIES (ATM 201-229) 
Code Scaffold Code Scaffold 
ATM 201 
N
N N
N
N
H2N
O
PO
O
O
 
ATM 202 
 
N
N N
N
N
H2N
O
PO
O
O
O
 
ATM 203 
N
N N
N
N
H2N
O
PO
O
O
N
Me
 
ATM 204 
 
N
N N
N
H2N
O
PO
O
ONH
 
ATM 205  
N
N N
N
NH
H2N
O
PO
O
O
HN
 
ATM 206  
 
N
N N
N
NH
H2N
O
PO
O
O
 
ATM 207 
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O
PO
O
O
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ATM 211 
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ATM 221 
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5. TABLE 3: PHYSICAL DATA  
Code No. MF/MW Physical  Appearance Mp/
oC TLC (C:M)/Rf 
Time/ 
%Yields 
ATM 201 C18H31N6O4P/426.45 Oily liquid - 6.5:3.5/0.425 5:30/74 
ATM 202 C18H31N6O5P/442.45 White solid 129-130 9.0:1.0/0.333 6:15/85 
ATM 203 C19H34N7O4P/455.49 Oily liquid - 9.0:1.0/0.369 4:30/79 
ATM 204 C20H35N6O4P/454.50 White solid 142-143 9.5:0.5/0.289 6:15/65 
ATM 205 C24H34N7O4P/515.55 Yellow solid 139-140 9.0:1.0/0.368 7:30/55 
ATM 206 C17H31N6O4P/414.44 Yellow Solid 125-127 9.2:0.8/0.299 5:30/61 
ATM 207 C19H33N6O4P/440.48 Oily liquid - 9.0:1.0/0.389 4:15/69 
ATM 208 C18H31N7O4P/440.46 White solid 114-116 8.5:1.5/0.258 6:30/57 
ATM 209 C18H33N6O4P/428.47 White solid 110-112 8.8:1.2/0.311 3:30/68 
ATM 210 C20H30N7O4P/463.47 Oily liquid - 8.5:1.5/0.278 4:40/52 
ATM 211 C19H34N7O4P/471.49 Oily liquid - 8.0:2.0/0.325 5:00/59 
ATM 212 C25H38N7O4P/531.59 Oily liquid - 9.5:0.5/0.311 4:15/54 
ATM 213 C16H30N7O4P/415.43 White solid 112-114 8.5:1.5/0.247 6:30/68 
ATM 214 C18H32N7O5P/457.46 Oily liquid - 9.0:1.0/0.268 5:45/51 
ATM 215 C19H35N8O4P/470.51 Yellow solid 121-123 8.5:1.5/0.250 5:00/46 
ATM 216 C19H33N6O4P/440.48 White solid 154-156 9.0:1.0/0.311 5:15/64 
ATM 217 C21H31N6O4P/462.48 Yellow solid 131-133 8.8:1.2/0.355 6:00/78 
ATM 218 C16H27N6O6P/430.40 Oily liquid - 9.0:1.0/0.247 5:30/55 
ATM 219 C18H33N6O5P/444.47 Yellow solid 142-143 8.6:1.4/0.274 5:45/52 
ATM 220 C24H36N7O4P/517.56 Fluppy solid 129-130 8.5:1.5/0.389 4:30/58 
ATM 221 C20H36N7O4P/469.52 Oily liquid - 9.0:1.0/0.251 5:15/65 
ATM 222 C17H32N7O4P/429.45 White solid 134-136 9.0:1.0/0.398 4:30/60 
ATM 223 C16H29N6O4P/484.57 White solid 139-140 8.4:1.6/0.236 7:30/71 
ATM 224 C20H37N6O4P/456.52 Oily liquid - 9.2:0.2/0.351 7:00/61 
ATM 225 C17H31N6O4P/414.44 Yellow solid 124-125 8.6:1.4/0.299 6:15/72 
ATM 226 C18H33N6O4P/428.47 Yellow solid 128-130 8.6:1.4/0.300 6:00/76 
ATM 227 C18H27N6O5P/438.42 Oily liquid - 9.0:1.0/0.240 5:45/59 
ATM 228 C16H29N6O4P/400.41 Oily liquid - 8.5:1.5/0.313 5:15/62 
ATM 229 C14H25N6O5P/388.36 Oily liquid - 8.8:1.2/0.217 4:30/67 
 
MF=Molecular Formula 
MW=Molecular Weight 
C:M=Chloroforom:Methanol  
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6. SPECTRAL DISCUSSION  
1H NMR Spectra 
Proton NMR spectra were recorded on Bruker 300 or 400MHz (Avance-II) instruments 
using CDCl3 and D2O as the solvents with tetramethylsilane (TMS) as the respective 
internal standard. Chemical shifts were recorded in (δ) and coupling constants were 
recorded in Hertz (J). Number of protons found in NMR is concomitant with the 
theoretical value. The splitting pattern doublet-multiplet concretely indicates the presence 
of isopropyl group in the structure. Two methylene group shows the triplets having 
varying the δ values. One more doublet is also observed, instead of singlet due to 
presence of methylene group. The doublet pattern of methylene group is due to the 
presence of adjacent “P” atom, which will split by J value ~8.5. The H-8 proton of the 
purine moiety shows the chemical shift ~7.6-7.9 δ, which is slight downfield than the 
spectra of the small library of 9-isomer (i.e. ATM 301-329). The position of two protons 
of –NH2 group shows the broad singlet but it may sometimes merge with the multiplet. 
Further details of each compounds is mentioned in subsequent pages. 
13 C NMR Spectra 
13C NMR spectra were recorded on Bruker 400MHz instrument using CDCl3 as the 
solvent with tetramethylsilane (TMS) as the respective internal standard. The chemical 
shifts were recorded in ppm. Numbers of carbon present in the purine molecules 
investigate are comparable with the experimental and 13C spectral evidences. The C-2 
carbon of the purine ring is the most downfield of the spectrum appears around 163. The 
four methyl group shows around 24. Sometimes all the methyl group shows single peak, 
instead of four different peaks. The characteristic splitting is observed in the form of 
doublet at ~71 δ. This doublet is obviously due to the presence of “P” atom near the 
methylene group.  
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DEPT 135 
The presence of all three methylene groups, four methyl groups and  methine is also 
confirmed by  DEPT-135 experiment of the selected compounds. The position of C-8 is 
observed at ~137 δ. The spectral pattern is varying depending upon the type of 
substitution at position-6. 
APT Experiment 
The position and presence of methyl, methylene, methine and quaternary carbon is also 
confirmed by APT experiment too. This experiment suffices to prove the carbon-skeleton 
of the molecule. 
FT-IR Spectra 
IR spectra were recorded on Shimadzu FTIR-8400 using KBr disc and DRS techniques. 
The percentage transmittance is given in cm-1. The presence of primary and secondary 
amine was confirmed at ~3300 as doublet and singlet. In the aromatic C=C stretching is 
observed at ~1650. The C-H stretching is observed at ~2950. N-H stretching is observed 
at ~1580. Characteristic P=O stretching is observed at ~1550. C-N, aromatic and aliphatic 
is stretched at ~1350 and 1250 respectively. The C-O stretching of the aliphatic ether is 
observed at ~1100. Rests of the spectral information are given in the spectral data. IR 
spectroscopy does not provide the strong evidence for the skeleton of the compounds. 
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Mass spectra 
Mass spectra were recorded on Shimadzu GCMS-QP2010 by EI technique. Both 
molecular ion peak and base peak of all the compounds shows at different m/z value. 
Different fragmentation pattern is seen in synthesized compounds. 
Elemental Analysis 
Elemental analysis of the compounds was carried out on Elementar Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned.   
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7. SPECTRAL DATA 
Diisopropyl(2-(2-amino-6-pyrolidine-1-yl)-7H-purine-7-yl)ethoxy)methyl 
phosphonate (ATM 201) 
MS (EI, m/z): 426(M+, 33), 427(M+1, 20), 411(18), 397(2), 384(3), 369(4), 355(2), 
341(6), 313(5), 293(4), 272(3), 261(5), 247(79), 231(100), 219(60), 204(100), 187(16), 
176(100), 162(67), 149(47), 135(79), 123(13), 108(14), 95(18), 70(50), 68(9), 55(12), 
43(89), 41(32). 
Anal. Calc.: C 50.70%, H 7.33%, N 19.71%; Anal. Observed: C 50.65%, H 7.35%, N 
19.69%.  
Diisopropyl (2-(2-amino-6-morpholino)-7H-purine-7-yl)ethoxy) methyl 
phosphonate (ATM 202) 
1H NMR (CDCl3): δ 7.774(s, 1H, H-8), 4.794(brs, 2H, -NH2), 4.503-4.398(m, 2H, 2x-
CH), 4.141(t, 2H, -CH2), 3.680-3.605(m, 6H, -CH2), 3.449(d, 2H, J=7.94, POCH2), 
3.102(s, 4H, -CH2), 1.092-1.036(q, 12H, 4x-CH3). 
13C NMR (CDCl3): δ 164.63, 159.79, 147.54, 135.85, 110.36, 72.01, 71.89, 71.73, 67.64, 
67.45, 66.80, 65.42, 50.89, 47.20, 24.40, 24.36, 24.31.  
IR (KBr Pellet): 3537.57(1°-NH2), 2978.19(C-H), 1643.41(C=C), 1560.46(N-H), 
1352.14(C-N, Aromatic), 1255.7(C-N, Aliphatic), 1159.26(P=O), 1111.03(C-O), 
879.57(P-O). 
MS (EI, m/z): 442(M+, 22), 444(M+2, 5), 427(10), 412(2), 397(10), 385(9), 369(2), 
357(5), 341(10), 327(3), 313(10), 301(6), 283(3), 272(1), 263(28), 247(62), 233(53), 
220(100), 203(18), 190(41), 177(27), 162(35), 150(17), 135(51), 123(6), 108(10), 95(16), 
80(5), 56(10), 43(45), 41(16). 
Anal. Calc.: C 48.86%, H 7.06%, N 18.99%; Anal. Observed: C 48.89%, H 7.11%, N 
18.91%.  
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Diisopropyl (2-(2-amino-6-(4-methylpiperazine-1-yl)-7H-purine-7-yl)ethoxy) 
methyl phosphonate (ATM 203) 
IR (KBr Pellet): 3255(1º-NH2), 3226.7(=CH), 2980.8(C-H), 1568.0(N-H), 1373.2(C-N, 
Aromatic), 1284.5(C-N, Aliphatic), 1213.1(P=O), 1118.6(C-O), 936.4(P-O). 
MS (EI, m/z): 455(M+, 8), 456(M+1, 5), 440(10), 427(1), 412(2), 398(6), 385(22), 
372(56), 354(7), 343(31), 325(3), 313(2), 301(56), 283(13), 276(5), 253(5), 242(2), 
233(5), 219(7), 203(6), 193(42), 177(42), 163(36), 150(100), 135(16), 121(3), 108(5), 
95(10), 70(28), 56(11), 43(52), 41(12). 
Anal. Calc.: C 50.10%, H 7.52%, N 21.53%; Anal. Observed: C 50.16%, H 7.56%, N 
21.52%.  
Diisopropyl (2-(2-amino-6-cyclohexylaminno)-7H-purine-7-yl)ethoxy)methyl 
phosphonate (ATM 204) 
1H NMR (CDCl3): δ 7.634(s, 1H, H-8), 5.798(d, 1H, J=7.14, -NH), 4.725(brs, 2H, -
NH2), 4.703-4.595(m, 2H, 2x-CH), 4.357(t, 2H, -CH2), 4.074(t, 3H), 3.745(d, 2H, 
J=6.132, -POCH2), 2.077(m, 2H, -CH2), 1.786-1.657(m, 3H), 1.497-1.375(m, 2H), 
1.296(d, 8H), 1.219(d, 7H).   
13C NMR (CDCl3): δ 161.81, 160.15, 151.66, 143.90, 107.84, 73.27, 73.23, 71.81, 67.88, 
65.69, 49.32, 47.62, 33.62, 26.16, 25.39, 24.37, 24.32, 24.25. 
IR (KBr Pellet): 3278(1º-NH2), 3239.2(=CH), 2979.7(C-H), 1561(N-H), 1377.5(C-N, 
Aromatic), 1289.2(C-N, Aliphatic), 1217.2(P=O), 1122(C-O), 955.3(P-O). 
MS (EI, m/z): 454(M+, 20), 455(M+1, 5), 439(5), 425(1), 411(4), 397(10), 383(1), 
369(8), 353(4), 341(2), 327(4), 313(5), 295(2), 289(3), 275(40), 259(70), 245(5), 232(38), 
217(5), 203(6), 193(24), 177(30), 163(12), 150(100), 135(17), 123(6), 108(9), 95(9), 
81(6), 56(12), 43(41), 41(20). 
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Anal. Calc.: C 52.85%, H 7.76%, N 18.49%; Anal. Observed: C 52.86%, H 7.81%, N 
18.46%.  
Diisopropyl(2-(6-(2-(1H-indole-3-yl)ethylamino)-2-amino-7H-purine-7-yl) 
ethoxy) methyl phosphonate (ATM 205) 
IR (KBr Pellet): 3559.78(1°-NH2), 3455.51(2°-NH2), 2971.21(=CH), 1641.67(C=C), 
1600.09(N-H), 1361.00(C-N, Aromatic), 1241.78(C-N, Aliphaitc), 1219.34(P=O), 
1111.61(C-O), 780.69(P-O).  
Anal. Calc.: C 55.91%, H 6.65%, N 19.02%; Anal. Observed: C 55.93%, H 6.68%, N 
19.01%.  
Diisopropyl (2-(2-amino-6-(diethylamino)-7H-purine-7-yl)ethoxy) methyl 
phosphonate (ATM 209) 
IR (KBr Pellet): 3410.49 & 3335.20(1º-NH2), 3239.67(2º-NH2), 2971.29(=CH), 
1651.51(C=C), 1581.79(N-H), 1371.09(C-N, Aromatic), 1251.88(C-N, Aliphatic), 
1188.45(P=O), 1151.09(C-O), 889.19(P-O). 
Anal. Calc.: C 50.46%, H 7.76%, N 19.61%; Anal. Observed: C 50.49%, H 7.77%, N 
19.59%.  
Diisopropyl (2-(2-amino-6-(4-benzylpiperazine-1-yl)-7H-purine-7-yl)ethoxy) 
methyl phosphonate (ATM 212) 
1H NMR (CDCl3): 7.956(s, 1H, H-8), 7.344(d, 5H, Ar-H), 4.926(brs, 2H, -NH2), 4.689-
4.627(m, 2H, 2x-CH), 4.342(s, 2H, -CH2), 3.849(s, 2H, -CH2), 3.646(d, 2H, J=7.84, 
POCH2), 3.542(s, 2H), 3.339(s, 4H), 2.594(s, 4H), 1.303-1.255(m, 12H). 
13C NMR (CDCl3): 163.94, 159.3, 156.39, 147.05, 137.69, 129.13, 128.38, 127.32, 
109.91, 100.02, 71.72, 71.62, 71.36, 66.97, 65.3, 62.99, 52.66, 49.98, 46.89, 24.02. 
MS (EI, m/z): 531, (M+,20), 532(M+1), 516(9), 440(4), 430(2), 398(5), 385(22), 372(53), 
352(3), 343(26), 325(1), 313(2), 301(40), 283(10), 272(3), 253(5), 242(1), 233(3), 
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219(11), 205(9), 193(41), 177(39), 163(36), 150(91), 135(12), 121(5), 108(4), 91(100), 
83(4), 56(14), 45(4). 
Anal. Calc.: C 56.49%, H 7.21%, N 18.44%; Anal. Observed: C 56.52%, H 7.25%, N 
18.40%.  
Diisopropyl (2-(2-amino-6-(benzylamino)-7H-purine-7-yl)ethoxy) methyl 
phosphonate (ATM 217) 
1H NMR (CDCl3): 7.657(s, 1H, H-8), 7.377-7.216(m, 5H, Ar-H), 6.683(brs, 1H, -NH), 
5.094(brs, 1H, -NH2), 4.668-4.527(m, 2H, 2x-CH), 4.397(t, 2H), 3.951(t, 2H), 3.68(s, 
2H), 3.535(d, 2H, J=7.2, -POCH2), 1.273-1.226(m, 12H, 4x-CH3). 
13C NMR (CDCl3): 162.33, 161.51, 141.19, 129.23, 128.14, 127.19, 108.02, 72.15, 
71.35, 71.05, 68.91, 68.14, 42.05, 24.12. 
IR (KBr Pellet): 3491.0(2o-NH2), 3278.98(1º-NH2), 3179.48(=CH), 2983.11(C-H), 
1630(C=C), 1588.51(N-H), 1375.63(C-N, Aromatic), 1278.19(C-N, Aliphatic), 1175.95 
(P=O), 1123.60(C-O), 912.45(P-O). 
Anal. Calc.: C 54.54%, H 6.76%, N 18.17%; Anal. Observed: C 54.59%, H 6.10%, N 
18.15%.  
Diisopropyl (2-(2-amino-6-(4-phenylpiperazine-1-yl)-7H-purine-7-yl)ethoxy) 
methyl phosphonate (ATM 220) 
1H NMR (CDCl3): 7.999(s, 1H, H-8), 7.315-7.275(m, 2H, Ar-H), 6.971(d, 2H, J=7.96, 
Ar-H), 6.907(t, 1H, Ar-H), 4.959(brs, 2H, -NH2), 4.699-4.618(m, 2H, 2x-CH), 4.401(t, 
2H, -CH2), 3.876(t, 2H, -CH2), 3.659(d, 2H, J=8, POCH2), 3.474(t, 4H), 3.322(t, 4H), 
1.336-1.244(m, 12H, 4x-CH3). 
13C NMR (CDCl3): 164.05, 159.35, 156.35, 151.03, 147.18, 129.24, 120.39, 116.38, 
110.07, 71.68, 71.59, 71.39, 66.97, 65.31, 50.12, 49.04, 46.88, 29.69, 24.01. 
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IR (KBr Pellet): 3385.2 & 3341(1o–NH2), 3215.9(=CH), 2985.17(C-H), 1645.31(C=C), 
1579.19(N-H), 1338.02(C-N, Aromatic), 1235.09(C-N, Aromatic), 1157.45(P=O), 
1109.03(C-O),  835.31(P-O), 786.89(N-H, opp). 
MS (EI, m/z): 517(M+, 21), 518(M+1, 518), (M-1, 516), 502(19), 474(3), 460(3), 427(4), 
416(6), 399(7), 385(73), 372(82), 357(4), 343(67), 322(7), 310(7), 301(90), 283(21), 
267(15), 253(9), 242(3), 233(5), 219(15), 205(21), 193(50), 177(45), 163(67), 150(100), 
132(33), 118(9), 104(40), 95(21), 77(22), 56(9), 43(44), 41(20). 
Anal. Calc.: C 55.70%, H 7.01%, N 18.94%; Anal. Observed: C 55.77%, H 7.05%, N 
18.90%.  
Diisopropyl (2-(2-amino-6-(4-ethyllpiperazine-1-yl)-7H-purine-7-yl)ethoxy) 
methyl phosphonate (ATM 221)  
1H NMR (CDCl3): 7.974(s, 1H, H-8), 4.969(brs, 2H, -NH2), 4.709-4.628(m, 2H, 2x-CH), 
4.357(t, 2H, -CH2), 3.86(t, 2H, -CH2), 3.656(d, 2H, J=7.96, -CH2), 3.404(s, 3H), 
2.642(brs, 5H), 2.529(q, 3H), 1.333-1.261(m, 12H, 4x-CH3), 1.151(t, 3H) 
13C NMR (CDCl3): 163.91, 159.3, 156.22, 147.08, 109.84, 71.7, 71.61, 71.41, 66.98, 
65.32, 52.43, 52.23, 49.71, 46.94, 24.06, 11.78 
MS (EI, m/z): 469(M+, 11), 470(M+1, 7), 454(7), 440(2), 426(1), 412(2), 398(5), 
385(17), 372(50), 357(1), 343(25), 325(2), 313(2), 301(43), 283(10), 274(5), 253(5), 
247(3), 233(2), 219(9), 203(6), 193(44), 177(40), 163(28), 150(100), 135(14), 113(5), 
98(5), 84(37), 70(8), 56(23), 43(40), 41(14). 
Anal. Calc.: C 51.16%, H 7.73%, N 20.88%; Anal. Observed: C 51.20%, H 7.76%, N 
20.85%.  
Diisopropyl (2-(2-amino-6-(octylamino)-7H-purine-7-yl)ethoxy) methyl 
phosphonate (ATM 223) 
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1H NMR (CDCl3): 7.651(s, 1H, H-8), 6.019(brs, 1H, -NH), 4.686-4.624(m, 4H, -NH2 
and –2xCH), 4.389(t, 2H, -CH2), 4.032(t, 2H, -CH2), 3.746(d, 2H, J=7.2, POCH2), 3.533-
3.485(m, 2H), 1.658(t, 2H, -CH2), 1.367-1.207(m, 22H, 6x-CH2 and 4x-CH3), 0.883(t, 
3H, -CH3).  
13C NMR (CDCl3): 159.83, 152.46, 71.44, 71.37, 67.42, 65.76, 40.94, 31.85, 29.66, 
29.42, 29.31, 27.20, 24.01, 23.96, 23.9, 23.84, 22.66, 11.6. 
MS (EI, m/z): 484(M+, 39), 485(M+1, 12), 469(10), 455(5), 441(12), 399(25), 385(35), 
357(10), 343(21), 315(10), 305(65), 289(96), 262(41), 247(6), 233(6), 219(9), 205(18), 
191(40), 177(41), 163(44), 150(83), 135(30), 123(10), 108(15), 95(22), 81(6), 57(14), 
43(100), 41(40). 
Anal. Calc.: C 54.53%, H 8.53%, N 17.34%; Anal. Observed: C 54.57%, H 8.58%, N 
17.32%.  
Diisopropyl (2-(2-amino-6-(propylamino)-7H-purine-7-yl)ethoxy) methyl 
phosphonate (ATM 225) 
1H NMR (CDCl3): 7.662(s, 1H, H-8), 6.186(s, 1H, -NH), 5.065(brs, 2H, -NH2), 4.683-
4.618(m, 2H, 2x-CH), 4.423(t, 2H, -CH2), 4.006(t, 2H, -CH2), 3.729(d, 2H, J=7.6, -
POCH2), 3.465(q, 2H, -CH2), 1.671(q, 2H, -CH2), 1.303-1.189(m, 12H, 4x-CH3), 0.981(t, 
3H, -CH3). 
13C NMR (CDCl3): 160.48, 159.45, 152.13, 143.42, 107.46, 73.2, 71.45, 71.38, 67.35, 
65.69, 42.64, 23.99, 23.95, 23.87, 23.82, 22.73, 11.6.  
IR (KBr Pellet): 3291.59(1º-NH2), 3179.78(2º-NH2), 3099.75(=CH), 2987.88(C-H), 
1649.41(C=C), 1589.12(N-H), 1375.05(C-N, Aromatic), 1281.69(C-N, Aliphatic), 
1180.55(P=O), 1180.19(C-O), 919.35(P-O). 
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MS (EI, m/z): 414(M+, 30), 415(M+1, 8), 399(8), 385(19), 357(4), 343(18), 329(5), 
313(9), 301(25), 283(8), 272, 249(2), 235(57), 219(100), 205(9), 192(60), 177(19), 
163(35), 150(55), 135(20), 123(7), 108(10), 95(16), 81(5), 57(8), 43(64), 41(23). 
Anal. Calc.: C 49.27%, H 7.54%, N 20.28%; Anal. Observed: C 49.32%, H 7.56%, N 
20.25%.  
Diisopropyl (2-(2-amino-6-(butylamino)-7H-purine-7-yl) ethoxy)methyl 
phosphonate (ATM 226) 
1H NMR (CDCl3): 7.649(s, 1H, H-8), 6.034(brs, 1H, -NH), 4.777(brs, 2H, NH2), 4.681-
4.631(m, 2H, 2x-CH), 4.392(t, 2H, -CH2), 4.017(t, 2H, -CH2), 3.74(d, 2H, J=7.2, 
POCH2), 3.51(q, 2H, -CH2), 1.639(q, 2H, -CH2), 1.455-1.399(m, 2H, -CH2), 1.306-
1.201(m, 12H, 4x-CH3), 0.974(t, 3H, -CH3). 
13C NMR (CDCl3): 160.40, 159.67, 152.11, 143.11, 107.65, 73.23, 73.16, 71.46, 67.39, 
65.74, 40.6, 31.71, 29.69, 24.00, 23.96, 23.88, 23.84, 20.28, 13.94. 
IR (KBr Pellet): 3319.31(1º-NH2), 3181.29(2º-NH2), 3081.75(=CH), 2985.78(C-H), 
1649.36(C=C), 1595.19(N-H), 1371.9(C-N, Aromatic), 1289.69(C-N, Aliphatic), 
1177.52(P=O), 1113.11(C-O), 949.41(P-O).   
MS (EI, m/z): 428(M+, 35), 429(M+1, 9), 413(9), 399(9), 385(26), 343(24), 327(10), 
315(10), 301(29), 249(62), 233(100), 219(10), 206(60), 191(25), 177(31), 163(41), 
150(55), 135(24), 123(8), 108(13), 95(19), 57(9), 43(64), 41(29). 
Anal. Calc.: C 50.46%, H 7.76%, N 19.61%; Anal. Observed: C 50.58%, H 7.79%, N 
19.58%.  
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8. SPECTRA OF THE REPRESENTATIVE COMPOUNDS 
1H NMR Spectrum of ATM-204 
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13C NMR Spectrum of ATM-204 
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EI-MS Spectrum of ATM-204 
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1H NMR Spectrum of ATM-221 
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13C NMR Spectrum of ATM-221 
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EI-MS Spectrum of ATM-221 
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1H NMR Spectrum of ATM-223 
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13C NMR Spectrum of ATM-223 (APT) 
Bad Resolved Spectrum (Carbons of the aromatic nucleus are not resolved) 
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1H NMR Spectrum of ATM-225 
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13C NMR Spectrum of ATM-225 (APT) 
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1H NMR Spectrum of ATM-226 
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13C NMR Spectrum of ATM-226 (APT) 
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FT-IR Spectra of ATM-202 and ATM-204 
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1. INTRODUCTION 
 
Pharmacological Profile 
 
The biological activity of pyrazolo[3,4-d]pyrimidine are enlisted as follows. 
 
1.1 Phosphodiesterase 5 inhibitors (PDE5 inhibitors) 
 
1.2 CDK-inhibitors 
 
1.3 Antiproliferative activity 
 
1.4 Herbicidal activity 
 
1.5 Activity against Thromboembolic disease 
1.1 PDE5 inhibitors 
Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular 
second messengers cyclic AMP and cyclic GMP. [1–3] As essential regulators of cyclic 
nucleotide signaling with diverse physiological functions, PDEs are drug targets for the 
treatment of various diseases, including heart failure, depression, asthma, inflammation 
and erectile dysfunction. [4–7] Of the 12 PDE gene families, cGMP-specific PDE5 
carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. 
It is well known as the target of Sildenafil citrate (Viagra) and other similar drugs 
(Vardenafil and Tadalafil) for the treatment of erectile dysfunction. Despite the pressing 
need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific 
PDE4 structures are currently available. [8,9] 
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The launch of sildenafil as the first oral treatment for male erectile dysfunction 
revolutionized the treatment of this disease. [10] 
Following the development of sildenafil, the PDE5 inhibitors with greater selectivity over 
phosphodiesterase type 6 (PDE6), since this enzyme is believed to be responsible for the 
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low incidence of adverse visual events, such as abnormalities in color vision, associated 
with high doses of sildenafil. SAR describing how this selectivity was achieved through 
the discovery of the pyridyl methyl analogue (4) has already been published. [11] 
Compound (4) is a potent PDE5 inhibitor displaying approximately 300-fold selectivity 
over canine cone PDE6. [11] In clinical trials, compound (4) showed dose-dependent 
increases in Cmax and AUC over the dose range 1-800 mg and increases in these 
parameters when coadministered with ketoconazole (a potent inhibitor of P-glycoprotein 
and CYP3A4). Further studies showed that compound (4) is a substrate for human P-
glycoprotein and CYP3A4, which explains the variations in pharmacokinetic data that 
arose when these species were either saturated or inhibited. As a consequence of these 
clinical data, we desired a PDE5 inhibitor with high and dose-independent oral 
bioavailability, since this would minimize the impact of any interactions with 
coadministered drugs in the clinic. [12] 
In order to identify a potent and selective PDE5 inhibitor with high and dose-independent 
oral bioavailability, to minimize the impact on Cmax of any interactions with 
coadministered drugs. In general, good solubility, high absorption across the intestinal 
wall, and low first-pass clearance are required for high oral bioavailability. [13] We 
focused on reducing the first-pass clearance of soluble, rule-of-five compliant [14] PDE5 
inhibitors to achieve this objective. The piperazine sulfonamide group is the primary site 
of metabolism in the sildenafil series. [15] Consequently, finding of a more metabolically 
stable replacement for this functionality. This led to a novel series of potent and selective 
PDE5 inhibitors, with a methyl ketone at the 5’-position of the 5-(2-alkoxy-3-pyridinyl)-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (5) template. These compounds are 
relatively small (MW<500) with moderate lipophilicity, and this results in good oral 
absorption. In addition, they have low clearance (the predominant metabolite in human 
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hepatocytes being the secondary alcohol) and a basic group attached at the N2 position, 
which provides good aqueous solubility via salt formation. The combination of these 
factors leads to high oral bioavailability in vivo. 
1.2 CDK-inhibitors 
 
Controlling the cell cycle by inhibition of the proteins that regulate its progression is an 
attractive strategy for addressing cancer and other diseases associated with abnormal 
cellular proliferation. [16] One family of such proteins, the cyclin-dependent kinases 
(CDKs), is made up of at least nine highly homologous enzymes that in association with 
specific regulatory subunits (cyclins) control progression of the cell cycle. [17] 
CDK/cyclin activity oscillates with cyclin expression/degradation and is further regulated 
by the action of several families of protein kinases and phosphatases. [18,19] A series of 
checkpoints serves to ensure the viability of progeny cells by preventing progression of 
cells with damaged DNA, an inappropriate chromosome count, or for which necessary 
structural features or conditions of nourishment do not exist. Passage through an initial 
G1 restriction point occurs upon release by the retinoblastoma protein (pRb) of the 
transcription factor E2F. [20] This is triggered by phosphorylation of several S/T residues 
on pRb, the primary substrate of CDK4/cyclin D. The fate of cells that enter G1 but 
which do not progress through the G1 or subsequent checkpoints is to undergo apoptosis. 
[21]  
Since tumor cells have misregulated cell cycles, it has been postulated that they may be 
especially sensitive to agents that restore checkpoint control. The importance of these 
kinase pathways is highlighted by the fact that the genes encoding CDKs, their cyclin 
partners, or their endogenous peptide inhibitors (CKIs) are mutated in a large proportion 
of human tumors. [22] One family of CKIs, the CIP/KIP class, is relatively promiscuous, 
having affinity for CDK2, CDK3, CDK4, and CDK6. [23] CDKIs in the INK4 class, 
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however, are highly selective for the closely related CDKs 4 and 6, suggesting the 
possibility of selective inhibition by small molecule mimics. For these reasons we sought 
to discover small-molecule protein kinase inhibitors that were selective for CDK/cyclin 
complexes, specifically CDK4/cyclin D1. How applicable this approach is to cancer 
chemotherapy is still an unresolved question. While a number of small-molecule CDK 
inhibitors have been disclosed, clinical experience is limited to the ATP-competitive 
agent flavopiridol. [24] Flavopiridol is relatively nonselective in its inhibition of the 
various CDKs; it also appears to inhibit other protein kinases. More recently, great strides 
have been made in the search for CDK-selective kinase inhibitors, including the 
discovery of a highly selective CDK4/cyclin D inhibitor by optimization of a non 
selective lead. [25] 
Markwalder, J. A. et al [26] identified a lead compound 4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidine-4-one (6)  by high-throughput screening of a subset of ~160000 compounds.  
The compound is active against CDK4/cyclin D1 was performed with a readout of 
percentage inhibition of pRb phosphorylation at 20µM. Discrete IC50 values were 
obtained for compounds that were active upon retest and appeared chemically attractive. 
This screening strategy identified several series of inhibitors with modest potency (IC50< 
50µM). 
HN
N N
N
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CF3
Cl
Cl
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The same author have patented [27] the following core structure (7) or its tautomeric 
structure (8) as a potent CDK inhibitors. 
HN
N
O
R6
R1
R3
Where R1= Hydrogen, alkyl, cycloalkyl, aralkyl, etc.
            R3=Hydrogen or lower alkyl
            R6= Substituted or unsubstituted aralkyl or heteroaralkyl
7
N
N
OH
R6
R1
R3
8
 
1.3 Antiproliferative activity 
 
The understanding of the fundamental biology of cancer increased dramatically in recent 
years [28] and has strongly impacted on both experimental and gradually also on clinical 
tumor therapy. We now believe that the future of tumor therapy is in the development of 
molecularly targeted agents that specifically block key mechanisms involved in 
development and progression of specific types of cancer. [29] Due to their critical role in 
tumor development and progression, molecules capable of inhibiting protein kinases are 
of central interest in targeted cancer therapy. In particular, tyrosine kinases (TKs) are 
enzymes that catalyze the specific phosphorylation of tyrosine residues on proteins. 
Protein tyrosine kinases (PTKs) participate in a wide variety of cellular activities 
including proliferation, secretion, adhesion, and responses to mitogens and stress. [30,31] 
The TK Src is the prototype member of the nonreceptor Src family of PTKs that include 
c-Yes, Fyn, c-Fgr, Lyn, Lck, Hck, Clk, Yrk, and c-Src. [32] In particular, the nonreceptor 
pp60c-Src PTK transduces signals that control the above cellular processes. [33-35] Src is 
activated following engagement of many different classes of cellular receptors and 
participates as a convergence point in different signaling pathways. [30,31,36] In this 
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regard, Src is a critical component of the signaling cascades initiated by tyrosine kinase-
linked receptors, such as the epidermal growth factor receptor (EGFR), and Gprotein 
coupled receptors and is directly associated with, and may regulate signaling via, the 
EGFR and HER-2/ neu receptor PTKs, [37,38] both of which are involved in cancer. 
Finally, Src overexpression and activation has been correlated with a large number of 
growth-regulatory processes in which Src participates. In particular, the Src protein is 
overexpressed in many tumors such as colon, breast, gastric, and prostatic tumors and 
plays a key role in controlling their proliferation and invasiveness. [39,40] On the basis of 
these  considerations, inhibitors of Src phosphorylation process may stop uncontrolled 
tumor cell growth and play an important role as new therapeutic agents for the treatment 
of cancer. During the past decade, examples of pyrazolo[3,4-d]-pyrimidines active as TKs 
inhibitors have been reported in the literature by different authors. Many of these 
compounds were highly active, and some of them have been largely used as standard or 
reference compounds and as a tool to set up in vitro assays and to prove their 
functionality. However, only a few demonstrated in vivo activity. As an example, 
approaches aimed at identifying ATP-competitive small molecules led to the 
characterization of derivatives as potent inhibitors of EGFR TK, (9) [41] while PP1 and 
PP2 (10) were described as very strong and selective inhibitors of the c-Src family of 
kinases. [42] Unfortunately, attempts to improve the biological profile of the later 
compounds have so far met little success. Following these studies, some other inhibitors, 
possessing different chemical structures and interesting c-Src inhibitory activity, have 
been recently reported. In particular, pyrrolo[2,3-d]pyrimidines have been described as 
selective and potent inhibitors of c-Src with inhibition potency of about 10nM and 20-
fold selectivity toward a panel of other TKs. [43] Other efforts directed to c-Src kinase 
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inhibitors included substituted 5,10-dihydropyrimido[4,5-b]quinolines, showing an in 
vitro c-Src inhibition activity in the nanomolar range. [44] 
N
N
N
N
H
NHR HN Cl
EGFR TK inhibitors
N
N
N
N
R
NH2
PP1: R= Me
PP2: R= Cl
(c-Src inhibitors)
9 10  
Schenone et al [45] synthesized and screened 4-aminopyrazolo[3,4-d]pyrimidines bearing 
various substituents at position 1 and 6. The synthesized compounds were screened for 
their antiproliferative activity against A431 cell line. The compound (11) shows the better 
inhibitors of the Src phosphorylation than the reference compound PP2 (10) 
N
N N
N
HN
MeS Cl
n-Bu
11  
The same author [46] have also synthesized a series of 4-aryl-4-amino-1H-pyrazolo[3,4-
d]pyrimidine and tested against tumor cell lines A431. Among the designed series the 
most potent having EC50 values 4.3 (12) and 1.4 (13). The values in the paranthesis 
denote the % inhibition of relative to the reference compound (AG1478) (14). 
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AG 1478EC50 4.3
 (112%)
EC50 1.4
 (146%)
12 13
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1.4 Herbicidal activity 
Liu, Z. –J. et al [47] have synthesized the small library of 6-(4-alkoxycarbonylalkoxy) 
phenoxy-3-alkylthio(alkylsulphonyl)-1-phenyl-5-(substituted phenyl)pyrazole[3,4-d] 
pyrimidin-4-ones and screened for the herbicidal activity. The herbicidal activity of all 
the compounds were taken against brassica napus (rape) and echinochloa crus-galli 
(barnyard grass) has been investigated at the dosage of 100 and 10mg/L using the 
reported procedure, [48] compared with the distilled water and 2,4-dichlorophenoxyl 
acetic acid (2,4-D), a commercially available herbicide in the market. The results of 
preliminary bioassay showed that some of them exhibit good herbicidal activities. Out of 
the designed series compounds (15), (16), (17), (18) and (19) showed more than 90% 
inhibitory rate to root of rape and barnyard grass at 100mg/L. It is also interesting to note 
that ethyl ester showed higher herbicidal activity than the corresponding methyl ester and 
n-propyl ester in general. The reason may be the hydrolysis of the products [49]. 
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1.5 Coagulation factor Xa 
 
Thromboembolic diseases remain the leading cause of death and disability in developed 
countries. This reality combined with the limitations of current therapies, has led to 
extensive efforts to develop novel antithrombotic agents. [50] Factor Xa has become a 
major focus of pharmaceutical intervention in the past decade because of its central role 
in the blood coagulation cascade. [51] Extensive preclinical and clinical evidence has 
demonstrated that inhibition of factor Xa is efficacious in both venous and arterial 
thrombosis. [52,53] Previously, it was demonstrated that a series of non-benzamidine N-
arylpyrazole carboxamides, represented by the 3-aminobenzisoxazole P1 analog 
Razaxaban (20), [54] were highly potent, selective, and orally bioavailable small 
molecule fXa inhibitors. Razaxaban has been shown to be efficacious in phase II deep 
vein thrombosis (DVT) clinical trials. [54] Furthermore, it was demonstrated that the 4-
methoxyphenyl residue could be an effective P1 group when combined with an optimized 
pyrazole-P4 subunit, as in compound (21). [55] Recently, bicyclic core variants of 2, 
represented by the 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one (22), [56] have been shown to 
retain potent binding affinity for fXa. These bicyclic variants were also expected to be 
less susceptible to in vivo amide hydrolysis, which in the case of N-arylpyrazole 
carboxamides such as (20) and (21) would liberate a biarylaniline fragment. However, 
compound (22) was found to have only modest efficacy in a rabbit rteriovenous (A-V) 
shunt thrombosis model [57] relative to razaxaban. This was rationalized on the basis of 3 
being 5-fold less potent than razaxaban. [56]  
Li, Y. –L. et al [58] have synthesized a small library and screened for their coagulation 
factor Xa. Among the designed series compounds (23), (24) and (25) are not only potent 
fXa inhibitors, but they are also highly selective versus relevant serine protease. 
Compound (21) has a favourable pharmacokinetic profile in dogs, with lower clearance 
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and longer half-life relative to Razaxaban. Furthermore, (23), (24) and (25) are highly 
efficacious in the rabbit A-V shunt thrombosis model, with activity comparable to the 
clinical candidate, razaxaban.  
FH
N
O
N N
NMe2.HCl
N
N
O N
NH2
F3C
    Razaxaban
fXa Ki = 0.19nM
            20
FH
N
O
N
N
F3C
SO2Me
MeO
           21
fXa Ki = 3.6nM
NN
N
O
N
N
H2NOC
MeO
            22
fXa Ki = 1.1 nM  
 
 
 
 
Synthesis of Pyrazolo[3,4-d]pyrimidine… 173
N
N
N
N
Me
O
Me
N
O N
NH2
N
N
N
N
Me
O
Me
O N
NH2
N OH
23 24
N
N
N
N
F3C
O
Me
N
O N
NH2
25  
 
 
 
Synthesis of Pyrazolo[3,4-d]pyrimidine… 174
2. SYNTHETIC APPROACHES 
 
SCHEME 1 [59] 
 
HN
N
H
O
O NHNH2
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N
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O HN
N
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O
O NH
N
NHR1
a
 
 
Reagent and condition: 
  
(a) Acetic acid, reflux (30min) 
 
SCHEME 2 [58] 
 
NO2
CN
F
a-c
CN
F
N
N
EtOOC NH2
COOMe
CN
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EtOOC N3
COOH
OTBSH2N
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N OCHO
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Reagents and conditions: 
 
(a) H2 (1 atm), 10% Pd/C, EtOH (95%); (b) NaNO2, HCl/H2O, 0oC; then ethyl 
cyanoacetate, NaOAc, MeOH/H2O, 0oC (55%); (c) BrCH2CO2Me, K2CO3, DMF, 90oC 
(10– 20%); (d) NaNO2, TFA, 0oC; then NaN3 (80%); (e) LiOH, THF/H2O (90%); (f) 
(COCl)2, CH2Cl2; then 4, DMAP, CH2Cl2 (70%); (g) SnCl2ÆH2O, MeOH, 65oC; (h) 95% 
HCO2H, reflux (70% for two steps)  
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SCHEME 3 [47] 
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Reagents and conditions: 
(a) PPh3/Br2 (b) ArNCO (c) K2CO3 
SCHEME 4 [46] 
EtOOC
H2N
Ph
OH
HN
N N
N
O
OH
Ph
a
1 2  
Reagent and condition: 
(a) HCONH2/ 190oC 
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SCHEME 5 [60]  
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Reagents and conditions: 
(a) i-Pr2NEt, Toluene, 1h, reflux (b) Cl3CCl3, PPh3, EDC, i-Pr2Net (c) R-NH2, CHCl3, 
reflux (d) K2CO3 or NaOMe or NaOH 
SCHEME 6 [61] 
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Reagents and conditions: 
 
(a) NIS, TFA, TFAA, reflux (b) (COCl)2, MDC, DMF, 0oC to RT, then 4-amino-5-ethyl-
1-(2-pyridinylmethyl)-1H-pyrazole-3-carboxamide, Py, MDC, rt (c) KHDMS, n-
propanol, reflux 
SCHEME 7 [62] 
 
NC
S S
NH2
O
a
N
N
S
R1
H2N
O
H2N
b or c HN
N N
N
O S
R1  
 
Reagents and conditions: 
 
(a) R1 NHNH2, MeOH, reflux (b) CH3CONH2, Heat (c) CH3CO2Et, NaOEt, EtOH 
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3. CURRENT WORK 
Present work and investigation deals with the Multi-component reactions of aldehydes, 
thiourea and pyrazolone by classical heating using Conc. HCl as the acid catalyst and by 
Microwave assisted synthesis employing HClO4-Fuller’s earth as the novel heterogeneous 
acid catalyst. To our best knowledge, this is the first report of HClO4-Fuller’s earth as the 
heterogeneous catalyst. The synthesis of the catalyst is shown in the experimental section. 
Various methodologies for the synthesis of pyrazolo[3,4-d]pyrimidines were reported by 
different authors which are depicted in the synthetic approaches in the introduction part. 
The introduction of phenyl ring at position-4 of the core structure is itself novel by 
employing one pot reaction condition i.e. Biginelli type reaction. In fact, current protocol 
is the novel protocol for the solution-phase synthesis of pyrazolo[3,4-d]pyrimidine by 
classical heating as well as Microwave Assisted Organic Synthesis (MAOS). In MAOS 
the overall yields of the products are higher than the conventional counterparts. 
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4. REACTION SCHEMES 
 
Step 1: Synthesis of 3-isopropyl-1H-pyrazol-5(4H)-one 
 
O
O O
NH2-NH2 .H2O
Acetic acid N N
H
O
 
 
Step 2: Synthesis of 4,5-dihydro-3-isopropyl-4-(substituted phenyl)-1H- 
pyrazolo[3,4-d]-pyrimidine-6(7H)-thiones 
H2N NH2
S
+ CHO
R NH
NH
S
R
N
N
H
N NH
O
HClO4/Fuller's earth
Acetonitrile/80oC
300W
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5. EXPERIMENTAL PROTOCOL 
 
Preparation of Catalyst 
A 70% aqueous perchloric acid (1.8 g, 12.5 mmol) was added to a suspension of Fuller’s 
earth 23.7 g) in ether (50 ml). The mixture was concentrated and the residue was heated at 
100 ◦C for 48 h under vacuum to give Fuller’s earth-HClO4 (0.5 mmol/g) as free flowing 
powder (50 mg = 0.025 mmol of HClO4). 
Step 1: 
Synthesis of 3-isopropyl-1H-pyrazol-5(4H)-one (1) 
Stirred β-ketoester (1 eq) and 2-3 drops of acetic acid at 20oC. To a stirred mixture, 
hydrazine hydrate (80%, 1.5eq) was added in a dropwise manner. The reaction mixture 
was heated, cooled by means of ice-bath. After the completion of addition of hydrazine 
hydrate, solid product was obtained, filtered by suction and washed with 2x20 ml of 
water. Then it was washed with methanol:water (50:50). It was dried at 40oC under 
vacuum for 2 hours. (Yields 75%), mp 185oC. The structure of the product was confirmed 
by 1H NMR and 13C NMR. 
Step 2: 
Synthesis of 4,5-dihydro-3-isopropyl-4-(substituted phenyl)-1H-pyrazolo[3,4-
d]-pyrimidine-6(7H)-thiones (ATM 401-415) 
Non-classical method for the synthesis of pyrazolo-pyrimidines  
The intimate mixture of banzaldehyde (1 eq), pyrazolone (1eq) and thiourea (1.2 eq) was 
stirred in acetonitrile (20ml) until clear solution was observed. Heterogeneous catalyst, 
HClO4/Fullers’s earth (20 mol%) was added to that. The resulting reaction mixture was 
subjected to microwave irradiation at 300W power at 80oC. The reaction was monitored 
by TLC (Chloroform:methanol::7:3, 1-2drpos of acetic acid). After completion of 
reaction, filtered at 60-65oC by suction and kept it in fridge for 2-3 hours. Solid product 
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was observed, filtered it, and washed with acetonitrile 2x10 ml. It was dried at 50OC for 2 
hours. (Yields 87-96%) 
Classical method for the synthesis of pyrazolo[3,4-d]pyrimidines (ATM 401-
415) 
The intimate mixture of banzaldehyde (1 eq), pyrazolone (1eq) and thiourea (1.2 eq) was 
stirred in acetonitrile (20ml) until clear solution was observed. Conc. HCl (3-4 drops) was 
added as the catalyst. The reaction mixture was allowed to reflux for an appropriate time. 
After the completion of reaction, the reaction mixture was cooled. In some reaction, even 
at room temperature the solid product was found. The products were filtered and washed 
with acetonitrile and dried in oven. The reaction time and percentage yields of the 
respective reactions are depicted in the Physical Data Table. 
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6. PLAUSIBLE MECHANISMS 
Path A 
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7. PHYSICAL DATA 
Synthesis of pyrazolo[3,4-d]pyrimidine by classical heating using conc. HCl as the acid 
catalyst and under microwave irradiation (300W) at 80oC by using heterogeneous catalyst 
(20 mol %) 
N
H
NH
S
R
N
N
H
ATM 401-415  
aConventional 
 heating 
Microwave  
irradiation Code 
no 
Substitutions 
(R) Products Yields 
(%) 
Time 
(h) 
Yields 
(%) 
Time 
(min) 
MW/MF 
ATM 401 2-NO2 ATM 401 72 5:30 87 3 C14H15N5O2S/317.37 
ATM 402 4-NO2 ATM 402 75 6:00 95 4 C14H15N5O2S/317.37 
ATM 403 H ATM 403 73 6:15 89 3 C14H16N4S/272.37 
ATM 404 3-Br ATM 404 76 5:00 85 5 C14H15BrN4S/351.26 
ATM 405 2-Cl ATM 405 80 7:00 92 2 C14H15ClN4S/306.81 
ATM 406 3-Cl ATM 406 75 7:30 92 3 C14H15ClN4S/306.81 
ATM 407 4-Cl ATM 407 78 6:00 90 4 C14H15ClN4S/306.81 
ATM 408 3-OH ATM 408 81 7:15 87 5 C14H16N4O6/288.37 
ATM 409 4-F,3-NO2 ATM 409 74 5:00 90 5 C14H14FN5O2S/335.36 
ATM 410 2-OH ATM 410 79 6:45 86 2 C14H16N4O6/288.37 
ATM 411 4-OH ATM 411 71 5:30 91 3 C14H16N4O6/288.37 
ATM 412 4-OMe ATM 412 78 6:30 90 3 C15H18N4OS/302.29 
ATM 413 3-NO2 ATM 413 77 5:45 92 4 C14H15N5O2S/317.37 
ATM 414 2-OMe ATM 414 80 6:30 88 2 C15H18N4OS/302.29 
ATM 415 3-OMe ATM 415 72 7:45 93 3 C15H18N4OS/302.29 
 
aConventional heating refers the heating in acetonitrile and using Conc. HCl as the acid 
catalyst. 
Note: The mp (oC) of all the compounds was checked up to 260oC by open capillary 
method, none of the compound melts below 260oC. 
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8. SPECTRAL DISCUSSION 
FT-IR Spectra 
IR spectra were recorded on Shimadzu FTIR-8400 using KBr disc and DRS techniques. 
The percentage transmittance is given in cm-1. The presence of isopropyl group shows at 
~1395 and 1365 wave numbers as doublet. It strongly indicates the presence of isopropyl 
group. The presence of amine shows at ~3450 wave numbers. The peak at ~1250 wave 
number indicates the presence of thiocarbonyl functionality. The SP2 =C-H will shows at 
~3100 wave numbers, while C=C shows at ~1649 wave numbers. Rests of the 
informations are given in the spectra of the compounds. 
1H NMR Spectra 
Proton NMR spectra were recorded on Bruker 300 and 400MHz(Avance-II) instruments 
using DMSO and TFA as the solvents with tetramethylsilane (TMS) as the respective 
internal standard. Chemical shifts were recorded in (δ) and coupling constants were 
recorded in Hertz (J). Number of protons found in NMR is concomitant with the 
theoretical value. The compounds are hardly soluble in the solvent like DMSO or TFA 
even on heating. The solution becomes hazy on dissolution. Even though some of the 
spectra were recorded for study.  
EI-MS Spectra 
EI-MS spectra were recorded on Shimadzu GC-MS QP-2010 by Electron Impact method. 
In all the compounds, the molecular weights were found to be 43 m/z less than the 
molecular ion peak. No particular fragmentation pattern is observed from the spectra. 
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9. SPECTRAL DATA 
3-isopropyl-1H-pyrazol-5(4H)-one (ATM 400) 
1H NMR: 10.336(brs, 2H), 5.217(s, 1H), 2.817-2.725(m, 1H, -CH) 1.1438(d, 6H, 2x-
CH3) 
13C NMR: 161.56, 151.28, 87.03, 26.51, 23.03 
4,5-dihydro-3-isopropyl-4-(2-nitrophenyl)-1H-pyrazolo[3,4-d]-pyrimidine-
6(7H)-thiones (ATM 401) 
EI-MS: 274, 263, 245, 233, 220, 205, 179, 143, 139, 115, 104, 77, 44 
IR: 3462.34 (2o –NH2), 3100.00(=C-H, SP2), 2868.24(C-H, Aliphatic), 1670.41(C=N), 
1649.19(C=C), 1533.46(N=O, Asymmetric), 1398.44(i-Pr) and 1368.00(i-Pr) as doublet, 
1250.00(C=S), 1080.00(C-N).  
4,5-dihydro-3-isopropyl-4-(4-nitrophenyl)-1H-pyrazolo[3,4-d]-pyrimidine-
6(7H)-thiones (ATM 402) 
IR: 3498.99(2o –NH2), 3150.00(=C-H, SP2), 2860.00(C-H, Aliphatic), 1671.00(C=N), 
1649.19(C=C), 1527.67(N=O, Asymmetric), 1398.44 and 1346.36 (i-Pr as doublet) 
1249.91(C=S),   1085.96(C-N).  
4,5-dihydro-3-isopropyl-4-(phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6(7H)-
thiones (ATM 403) 
EI-MS: 229, 227, 202, 182, 174, 158, 144, 138, 116, 101, 89, 75, 58, 51, 41 
IR: 3460.41(2o –NH2), 3140.00(=C-H, SP2), 2860.23(C-H, Aliphatic), 1670.00(C=N), 
1649.19(C=C), 1253.77(C=S), 1085.96(C-N).    
4,5-dihydro-3-isopropyl-4-(3-bromo phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 404) 
EI-MS: 310, 309, 308, 307, 279, 231, 205, 177, 161, 147, 130, 119, 103, 91, 77, 58, 51, 
41 
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IR: 34669.23(2o –NH2), 3125.40(=C-H, SP2), 2872.32(C-H, Aliphatic), 1662.26(C=N), 
1653.25(C=C), 1249.47(C=S), 1077.11(C-N), 1060 (Ar-Br).    
4,5-dihydro-3-isopropyl-4-(2-chloro phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 405) 
EI-MS: 265, 264, 263, 245, 233, 220, 205, 179, 143, 139, 115, 104, 77, 44 
IR: 3458.48(2o –NH2), 3117.07(=C-H, SP2), 2872.10(C-H, Aliphatic), 1675.00(C=N), 
1647.26(C=C), 1359.86(i-Pr), 1255.00(C=S), 1087.89(C-N), 1045.45(Ar-Cl).  
4,5-dihydro-3-isopropyl-4-(3-chloro phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 406) 
IR: 3464.27(2o –NH2), 3115.14(=C-H, SP2), 2866.32(C-H, Aliphatic), 1674.27(C=N), 
1645.33(C=C), 1398.44(i-Pr), 1278.85(C=S), 1089.82(C-N), 1050.45(Ar-Cl). 
4,5-dihydro-3-isopropyl-4-(4-chloro phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 407) 
IR: 3439.19(2o –NH2), 3116.00(=C-H, SP2), 2870.17(C-H, Aliphatic), 1674.00(C=N), 
1651.12(C=C), 1244.13(C=S), 1089.82(C-N), 1014.59(Ar-Cl).     
4,5-dihydro-3-isopropyl-4-(3-hydroxy phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-
6(7H)-thiones (ATM 408) 
EI-MS: 245, 231, 221, 200, 186, 168, 156, 144, 126, 112, 111, 97, 77, 65, 51, 44 
IR: 3487.42(2o –NH2), 3470.06(O-H), 2988.55(=C-H, SP2), 2872.10(C-H, Aliphatic), 
1676.20(C=N), 1649.19(C=C), 1247.99(C=S), 1161.19(C-O).      
4,5-dihydro-3-isopropyl-4-(4-fluoro-3-nitro phenyl)-1H-pyrazolo[3,4-d]- 
pyrimidine-6(7H)-thiones (ATM 409) 
IR: 3495.96(2o –NH2), 3145.23(=C-H, SP2), 2867.69(C-H, Aliphatic), 1685.15(C=N), 
1648.69(C=C), 1587.85(N=O, Asymmetric), 1397.89(i-Pr), 1275.52(C=S), 1207.85(Ar-
F), 1085.26(C-N).     
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4,5-dihydro-3-isopropyl-4-(2-hydroxy phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 410) 
IR: 3455.36(O-H), 2995.23(=C-H, SP2), 2855.69(C-H, Aliphatic), 1689.23(C=N), 
1651.52(C=C), 1246.00(C=S), 1179.22(C-O).      
4,5-dihydro-3-isopropyl-4-(4-hydroxy phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 411)  
IR: 3482.51(2o –NH2), 3451.02(O-H), 2978.36(=C-H, SP2), 2865.02(C-H, Aliphatic), 
1680.23(C=N), 1658.32(C=C), 1239.56(C=S), 1171.56(C-O).      
4,5-dihydro-3-isopropyl-4-(4-methoxy phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 412) 
IR: 3481.23(2o –NH2), 2978.25(=C-H, SP2), 2865.33(C-H, Aliphatic), 1661.20(C=N), 
1649.19(C=C), 1241.36(C=S), 1161.19(C-O, Aromatic), 1115.15(C-O, Aliphatic).      
4,5-dihydro-3-isopropyl-4-(3-nitro phenyl)-1H-pyrazolo[3,4-d]-pyrimidine- 
6(7H)-thiones (ATM 413) 
IR: 3498.99(2o –NH2), 3140.00(=C-H, SP2), 2865.17(C-H, Aliphatic), 1678.00(C=N), 
1649.19(C=C), 1583.61(N=O, Asymmetric), 1396.51(i-Pr), 12843.63(C=S), 1087.89(C-
N).    
4,5-dihydro-3-isopropyl-4-(2-methoxy phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 414) 
IR: 3485.69(2o –NH2), 2956.23(=C-H, SP2), 2878.00(C-H, Aliphatic), 1659.71(C=N), 
1648.50(C=C), 1245.23(C=S), 1165.28(C-O, Aromatic), 1123.89(C-O, Aliphatic).     
4,5-dihydro-3-isopropyl-4-(3-methoxy phenyl)-1H-pyrazolo[3,4-d]-pyrimidine-6 
(7H)-thiones (ATM 415) 
IR: 3489.63(2o –NH2), 2989.56(=C-H, SP2), 2875.00(C-H, Aliphatic), 1665.69(C=N), 
1651.45(C=C), 1245.26(C=S), 1169.23(C-O, Aromatic), 1120.26(C-O, Aliphatic).      
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10. SPECTRA OF THE REPRESENTATIVE COMPOUNDS 
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1H NMR Spectrum of ATM 410 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR Spectrum of ATM 413 
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1H NMR Spectrum of ATM 406 
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EI-MS Spectrum of ATM 403 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EI-MS Spectrum of ATM 404 
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EI-MS Spectrum of ATM 405 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EI-MS Spectrum of ATM 408 
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IR spectrum of ATM 401 
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IR spectrum of ATM 402 
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IR spectrum of ATM 403 
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IR spectrum of ATM 405 
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IR spectrum of ATM 406 
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IR spectrum of ATM 407 
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IR spectrum of ATM 408 
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IR spectrum of ATM 413 
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